Met, metastasis, motility and more (scientific article (publication date: December 2003))

cites work (P2860)

Q34044173	(-)-Epigallocatechin-3-gallate inhibits Met signaling, proliferation, and invasiveness in human colon cancer cells
Q47146475	18F-fluorodeoxyglucose uptake predicts MET expression in lung adenocarcinoma
Q37254713	3,3'-diindolylmethane rapidly and selectively inhibits hepatocyte growth factor/c-Met signaling in breast cancer cells
Q50964510	3D-spheroids: What can they tell us about pancreatic ductal adenocarcinoma cell phenotype?
Q48270323	89Zr-DFO-AMG102 Immuno-PET to Determine Local Hepatocyte Growth Factor Protein Levels in Tumors for Enhanced Patient Selection
Q38956369	A DNA aptamer to c-Met inhibits cancer cell migration.
Q39238952	A New Anti-c-Met Antibody Selected by a Mechanism-Based Dual-Screening Method: Therapeutic Potential in Cancer
Q28484582	A New C-Xyloside Induces Modifications of GAG Expression, Structure and Functional Properties
Q42745683	A New Transgenic Mouse Model of Heart Failure and Cardiac Cachexia Raised by Sustained Activation of Met Tyrosine Kinase in the Heart.
Q39473718	A Novel Kinase Inhibitor, INCB28060, Blocks c-MET–Dependent Signaling, Neoplastic Activities, and Cross-Talk with EGFR and HER-3
Q54478410	A Phase 1 dose-escalation study of the safety and pharmacokinetics of once-daily oral foretinib, a multi-kinase inhibitor, in patients with solid tumors.
Q38702212	A Phase II Study of the c-Met Inhibitor Tivantinib in Combination with FOLFOX for the Treatment of Patients with Previously Untreated Metastatic Adenocarcinoma of the Distal Esophagus, Gastroesophageal Junction, or Stomach
Q37323058	A c-Met inhibitor increases the chemosensitivity of cancer stem cells to the irinotecan in gastric carcinoma
Q33574838	A cascade of modules of a network defines cancer progression
Q91745248	A chemically unmodified agonistic DNA with growth factor functionality for in vivo therapeutic application
Q34129715	A common variant of the MACC1 gene is significantly associated with overall survival in colorectal cancer patients.
Q54649963	A comparison of the pharmacokinetics of the anticancer MET inhibitor foretinib free base tablet formulation to bisphosphate salt capsule formulation in patients with solid tumors.
Q42809894	A direct role for Met endocytosis in tumorigenesis.
Q39692077	A disintegrin and metalloproteinase-10 (ADAM-10) mediates DN30 antibody-induced shedding of the met surface receptor
Q33424270	A first-in-human study of AMG 208, an oral MET inhibitor, in adult patients with advanced solid tumors
Q24674115	A genetic variant that disrupts MET transcription is associated with autism
Q36732888	A germline variant N375S in MET and gastric cancer susceptibility in a Chinese population
Q35600773	A hepatocyte growth factor receptor (Met)−insulin receptor hybrid governs hepatic glucose metabolism
Q36777999	A high affinity hepatocyte growth factor-binding site in the immunoglobulin-like region of Met
Q41547622	A human recombinant IL-7/HGFβ hybrid cytokine enhances antitumor immunity in mice
Q27647900	A mechanistic basis for converting a receptor tyrosine kinase agonist to an antagonist
Q39584378	A mouse model for spatial and temporal expression of HGF in the heart.
Q35929320	A mutation of MET, encoding hepatocyte growth factor receptor, is associated with human DFNB97 hearing loss.
Q44303811	A non-randomized, open-label, single-arm, Phase 2 study of emibetuzumab in Asian patients with MET diagnostic positive, advanced gastric cancer
Q47164810	A novel G-quadruplex motif in the Human MET promoter region
Q38773268	A novel antagonist anti-cMet antibody with antitumor activities targeting both ligand-dependent and ligand-independent c-Met receptors
Q47350019	A novel bispecific c-MET/CTLA-4 antibody targeting lung cancer stem cell-like cells with therapeutic potential in human non-small cell lung cancer
Q33710008	A novel bispecific c-MET/PD-1 antibody with therapeutic potential in solid cancer
Q36804227	A novel immunoprecipitation strategy identifies a unique functional mimic of the glial cell line-derived neurotrophic factor family ligands in the pathogen Trypanosoma cruzi
Q34121606	A novel mouse CD133 binding-peptide screened by phage display inhibits cancer cell motility in vitro
Q34185858	A novel multipurpose monoclonal antibody for evaluating human c-Met expression in preclinical and clinical settings
Q30617722	A novel role for ezrin in breast cancer angio/lymphangiogenesis
Q40179159	A novel small molecule Met inhibitor, PF2362376, exhibits biological activity against osteosarcoma.
Q51031755	A phase 1 study of the c-Met inhibitor, tivantinib (ARQ197) in children with relapsed or refractory solid tumors: A Children's Oncology Group study phase 1 and pilot consortium trial (ADVL1111).
Q36685241	A phase 1/2 and biomarker study of preoperative short course chemoradiation with proton beam therapy and capecitabine followed by early surgery for resectable pancreatic ductal adenocarcinoma
Q37222790	A phase I dose-escalation study of LY2875358, a bivalent MET antibody, given as monotherapy or in combination with erlotinib or gefitinib in Japanese patients with advanced malignancies
Q49881127	A phase I study of tivantinib in combination with temsirolimus in patients with advanced solid tumors
Q33434042	A phase I trial of cabozantinib and gemcitabine in advanced pancreatic cancer
Q58164878	A positive feedback loop between hepatocyte growth factor receptor and β-catenin sustains colorectal cancer cell invasive growth
Q35603900	A rapid and sensitive LC-MS/MS method for evaluation of the absolute oral bioavailability of a novel c-Met tyrosine kinase inhibitor QBH-196 in rats
Q40324374	A role for fibronectin-leucine-rich transmembrane cell-surface proteins in homotypic cell adhesion
Q34091387	A systematic analysis on DNA methylation and the expression of both mRNA and microRNA in bladder cancer
Q30152630	A viral microRNA downregulates metastasis suppressor CD82 and induces cell invasion and angiogenesis by activating the c-Met signaling
Q49885756	ADAMTS-1 disrupts HGF/c-MET signaling and HGF-stimulated cellular processes in fibrosarcoma.
Q30361215	ARF-GEF cytohesin-2/ARNO regulates R-Ras and α5-integrin recycling through an EHD1-positive compartment
Q35188254	AUY922 effectively overcomes MET- and AXL-mediated resistance to EGFR-TKI in lung cancer cells
Q36949230	AXL and MET crosstalk to promote gonadotropin releasing hormone (GnRH) neuronal cell migration and survival
Q24546366	Ab-induced ectodomain shedding mediates hepatocyte growth factor receptor down-regulation and hampers biological activity
Q92190792	Aberrant RON and MET Co-overexpression as Novel Prognostic Biomarkers of Shortened Patient Survival and Therapeutic Targets of Tyrosine Kinase Inhibitors in Pancreatic Cancer
Q39503071	Aberrations of MET are associated with copy number gain of EGFR and loss of PTEN and predict poor outcome in patients with salivary gland cancer
Q27308835	Abl Kinases Regulate HGF/Met Signaling Required for Epithelial Cell Scattering, Tubulogenesis and Motility
Q37022410	Absent and abundant MET immunoreactivity is associated with poor prognosis of patients with oral and oropharyngeal squamous cell carcinoma
Q53280611	Accumulative copy number increase of MET drives tumor development and histological progression in a subset of ovarian clear-cell adenocarcinomas
Q102060844	Acquired MET amplification in non-small cell lung cancer is highly associated with the exposure of EGFR inhibitors and may not affect patients' outcome
Q89588384	Acquisition of chromosome instability is a mechanism to evade oncogene addiction
Q47303095	Activated HGF-c-Met Axis in Head and Neck Cancer
Q35053276	Activated MET is a molecular prognosticator and potential therapeutic target for malignant peripheral nerve sheath tumors
Q37705080	Activating Met mutations produce unique tumor profiles in mice with selective duplication of the mutant allele
Q33942266	Activation of HER family members in gastric carcinoma cells mediates resistance to MET inhibition.
Q36005545	Activation of MET pathway predicts poor outcome to cetuximab in patients with recurrent or metastatic head and neck cancer
Q38912773	Activation of PAX3-MET pathways due to miR-206 loss promotes gastric cancer metastasis
Q36383040	Activation of Pim Kinases Is Sufficient to Promote Resistance to MET Small-Molecule Inhibitors
Q51805635	Activation of Wnt signaling in the intestinal mucosa of Apc +/min mice does not cause overexpression of the receptor tyrosine kinase Met.
Q38488236	Activation of hepatocyte growth factor by urokinase-type plasminogen activator is ionic strength-dependent
Q58607358	Activation of hepatocyte growth factor/MET signaling initiates oncogenic transformation and enhances tumoraggressiveness in the murine prostate
Q45991749	Activation of the HGF/c-Met axis in the tumor microenvironment: A multispecies model.
Q37346174	Activity of Pan-Class I Isoform PI3K/mTOR Inhibitor PF-05212384 in Combination with Crizotinib in Ovarian Cancer Xenografts and PDX
Q37480801	Acyl-CoA synthetase VL3 knockdown inhibits human glioma cell proliferation and tumorigenicity
Q42575382	Adenomatous polyposis coli and Asef function downstream of hepatocyte growth factor and phosphatidylinositol 3-kinase
Q37341011	Adhesion proteins meet receptors: a common theme?
Q33410375	Adverse reactions to targeted and non-targeted chemotherapeutic drugs with emphasis on hypersensitivity responses and the invasive metastatic switch
Q54960197	Aggregation of lipid rafts activates c-met and c-Src in non-small cell lung cancer cells.
Q39753947	Agonist monoclonal antibodies against HGF receptor protect cardiac muscle cells from apoptosis.
Q41131252	Allosteric Peptide Activators of Pro-Hepatocyte Growth Factor Stimulate Met Signaling
Q53134538	Allosteric inhibition of c-Met kinase in sub-microsecond molecular dynamics simulations induced by its inhibitor, tivantinib
Q39249815	Alpha-synuclein elicits glucose uptake and utilization in adipocytes through the Gab1/PI3K/Akt transduction pathway
Q37514050	Alteration status and prognostic value of MET in head and neck squamous cell carcinoma
Q40191055	Amplification of apoptosis through sequential caspase cleavage of the MET tyrosine kinase receptor
Q33997141	An RNA interference phenotypic screen identifies a role for FGF signals in colon cancer progression
Q36855729	An antimetastatic role for decorin in breast cancer.
Q39141556	An iTRAQ based quantitative proteomic strategy to explore novel secreted proteins in metastatic hepatocellular carcinoma cell lines
Q38878552	An intramolecular G-quadruplex structure formed in the human MET promoter region and its biological relevance
Q33588267	An orally available small-molecule inhibitor of c-Met, PF-2341066, reduces tumor burden and metastasis in a preclinical model of ovarian cancer metastasis
Q30428363	An orally bioavailable c-Met kinase inhibitor potently inhibits brain tumor malignancy and growth
Q24633986	An overview of the c-MET signaling pathway
Q24561588	An uncleavable form of pro-scatter factor suppresses tumor growth and dissemination in mice
Q41205527	Analogs of the hepatocyte growth factor and macrophage-stimulating protein hinge regions act as Met and Ron dual inhibitors in pancreatic cancer cells
Q33649756	Analysis of progress and challenges for various patterns of c-MET-targeted molecular imaging: a systematic review
Q37262662	Analysis of receptor tyrosine kinase internalization using flow cytometry.
Q37904356	Androgen receptor-mediated gene repression
Q47138931	Andrographolide enhanced 5-fluorouracil-induced antitumor effect in colorectal cancer via inhibition of c-MET pathway
Q58850416	Angiogenic factors: role in esophageal cancer, a brief review
Q37372320	Angioinhibitory action of NK4 involves impaired extracellular assembly of fibronectin mediated by perlecan-NK4 association.
Q51568263	Angiopoietin-like protein 1 antagonizes MET receptor activity to repress sorafenib resistance and cancer stemness in hepatocellular carcinoma
Q37045324	Angiotensin receptor subtype mediated physiologies and behaviors: new discoveries and clinical targets
Q39576693	Anomalous inhibition of c-Met by the kinesin inhibitor aurintricarboxylic acid.
Q34459696	Anti-MET immunoPET for non-small cell lung cancer using novel fully human antibody fragments
Q42425557	Anti-apoptotic role of caspase-cleaved GAB1 adaptor protein in hepatocyte growth factor/scatter factor-MET receptor protein signaling
Q39109310	Anti-c-MET Nanobody - a new potential drug in multiple myeloma treatment.
Q37138521	Anti-c-Met antibodies recognising a temperature sensitive epitope, inhibit cell growth
Q38695456	Anti-c-Met antibody bioconjugated with hollow gold nanospheres as a novel nanomaterial for targeted radiation ablation of human cervical cancer cell
Q35713152	Anti-tumor activity of WK88-1, a novel geldanamycin derivative, in gefitinib-resistant non-small cell lung cancers with Met amplification.
Q35205410	Anti-vascular therapies in ovarian cancer: moving beyond anti-VEGF approaches.
Q38214511	Antibodies directed against receptor tyrosine kinases: current and future strategies to fight cancer
Q35688071	Antitumor Activity of SNX-2112, a Synthetic Heat Shock Protein-90 Inhibitor, in MET-Amplified Tumor Cells with or without Resistance to Selective MET Inhibition
Q58088158	Antitumor effects of SB injection in canine osteosarcoma and melanoma cell lines
Q38408987	Apigenin Inhibits Cancer Stem Cell-Like Phenotypes in Human Glioblastoma Cells via Suppression of c-Met Signaling
Q34314564	Apigenin and its impact on gastrointestinal cancers.
Q35866739	Aptamers Binding to c-Met Inhibiting Tumor Cell Migration
Q48295154	Arf6 and its ZEB1-EPB41L5 mesenchymal axis are required for both mesenchymal- and amoeboid-type invasion of cancer cells
Q38846677	Arf6 regulates tumour angiogenesis and growth through HGF-induced endothelial β1 integrin recycling
Q35245109	Artificial human Met agonists based on macrocycle scaffolds
Q24317786	Asef2 and Neurabin2 cooperatively regulate actin cytoskeletal organization and are involved in HGF-induced cell migration
Q44258322	Aspergiolides C and D: spirocyclic aromatic polyketides with potent protein kinase c-Met inhibitory effects
Q30014823	Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma
Q47589111	Assessment of de novo copy-number variations in Italian patients with schizophrenia: Detection of putative mutations involving regulatory enhancer elements
Q46830250	Assessment of pharmacokinetic interaction between rilotumumab and epirubicin, cisplatin and capecitabine (ECX) in a Phase 3 study in gastric cancer
Q35844122	Association of a MET genetic variant with autism-associated maternal autoantibodies to fetal brain proteins and cytokine expression
Q35185524	Association of angiogenic factors with prognosis in esophageal cancer
Q33766947	Association of genetic variation in the MET proto-oncogene with schizophrenia and general cognitive ability
Q33499383	Association of the actin-binding protein transgelin with lymph node metastasis in human colorectal cancer
Q36072790	Associations between hepatocyte growth factor, c-Met, and basic fibroblast growth factor and survival in endometrial cancer patients
Q34456779	Associations of VEGF/VEGF-receptor and HGF/c-Met promoter polymorphisms with progression/regression of retinopathy of prematurity.
Q35910172	Attraction or repulsion: a matter of individual taste?
Q36223356	Autocrine activation of the MET receptor tyrosine kinase in acute myeloid leukemia
Q47840737	Automatic generation of causal networks linking growth factor stimuli to functional cell state changes
Q34309227	Axitinib and crizotinib combination therapy inhibits bone loss in a mouse model of castration resistant prostate cancer
Q42355232	BRAF activates PAX3 to control muscle precursor cell migration during forelimb muscle development
Q98647417	Bacterial hepatocyte growth factor receptor agonist stimulates hepatocyte proliferation and accelerates liver regeneration in a partial hepatectomy rat model
Q84504964	Bacterial survival strategies suggest rethinking cancer cooperativity
Q39750624	Beta4 integrin activates a Shp2-Src signaling pathway that sustains HGF-induced anchorage-independent growth
Q33518531	Bi-directional SIFT predicts a subset of activating mutations
Q36411841	Biochemical and pharmacological characterization of human c-Met neutralizing monoclonal antibody CE-355621
Q37312433	Biochemical basis for the functional switch that regulates hepatocyte growth factor receptor tyrosine kinase activation
Q37956524	Biological aspects of angiogenesis in multiple myeloma.
Q28085247	Biology of MET: a double life between normal tissue repair and tumor progression
Q26751332	Biomarker development in MET-targeted therapy
Q30416864	Biomarkers in preclinical cancer imaging.
Q38163223	Biomarkers of renal cell carcinoma
Q80185223	Bladder cancer cell invasion is enhanced by cross-talk with fibroblasts through hepatocyte growth factor
Q34409663	Boolean approach to signalling pathway modelling in HGF-induced keratinocyte migration
Q37204613	Breaking the epithelial polarity barrier in cancer: the strange case of LKB1/PAR-4
Q28743545	Breast Cancer Cells Induce Cancer-Associated Fibroblasts to Secrete Hepatocyte Growth Factor to Enhance Breast Tumorigenesis
Q37750050	C-MET as a new therapeutic target for the development of novel anticancer drugs
Q38771978	C-Met as a potential target for the treatment of gastrointestinal cancer: Current status and future perspectives.
Q36101108	C-Met inhibitor MK-8003 radiosensitizes c-Met-expressing non-small-cell lung cancer cells with radiation-induced c-Met-expression
Q37564471	C-met inhibition blocks bone metastasis development induced by renal cancer stem cells.
Q38846272	CITED4 gene silencing in colorectal cancer cells modulates adherens/tight junction gene expression and reduces cell proliferation
Q38614582	CRISPR/Cas9: molecular tool for gene therapy to target genome and epigenome in the treatment of lung cancer
Q28511299	CXCR4 and Gab1 cooperate to control the development of migrating muscle progenitor cells.
Q33880064	Cabozantinib (XL184) Inhibits Growth and Invasion of Preclinical TNBC Models
Q39472261	Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth
Q47940756	Cabozantinib As Salvage Therapy for Patients With Tyrosine Kinase Inhibitor-Refractory Differentiated Thyroid Cancer: Results of a Multicenter Phase II International Thyroid Oncology Group Trial
Q90349862	Cabozantinib Exhibits Potent Antitumor Activity in Colorectal Cancer Patient-Derived Tumor Xenograft Models via Autophagy and Signaling Mechanisms
Q38658285	Cabozantinib in the treatment of hepatocellular carcinoma.
Q89704881	Cabozantinib inhibits AXL- and MET-dependent cancer cell migration induced by growth-arrest-specific 6 and hepatocyte growth factor
Q38160757	Cabozantinib: a novel agent with a dual mechanism of action for castration-resistant prostate carcinoma
Q28076334	Cancer Preventive Activities of Tea Catechins
Q61445595	Cancer cell migration on elongate protrusions of fibroblasts in collagen matrix
Q39841653	Cancer cells harboring MET gene amplification activate alternative signaling pathways to escape MET inhibition but remain sensitive to Hsp90 inhibitors
Q39651237	Cancer cell‐derived IL‐1α promotes HGF secretion by stromal cells and enhances metastatic potential in pancreatic cancer cells
Q37852296	Cancer prevention by tea: Evidence from laboratory studies
Q33693371	Cancer prevention by tea: animal studies, molecular mechanisms and human relevance
Q36600420	Cancer proteomics by quantitative shotgun proteomics
Q83213559	Cancer stem cells: an evolving concept
Q55251461	Cancer-associated fibroblasts induce epithelial-mesenchymal transition through secreted cytokines in endometrial cancer cells.
Q38843388	Cardiotoxin III Inhibits Hepatocyte Growth Factor-Induced Epithelial-Mesenchymal Transition and Suppresses Invasion of MDA-MB-231 Cells
Q38981340	Cardiotoxin III suppresses hepatocyte growth factor-stimulated migration and invasion of MDA-MB-231 cells
Q39233148	Cbl-independent degradation of Met: ways to avoid agonism of bivalent Met-targeting antibody
Q40803828	Cdc42 and phosphoinositide 3-kinase drive Rac-mediated actin polymerization downstream of c-Met in distinct and common pathways
Q41077215	Cell confluence regulates hepatocyte growth factor-stimulated cell morphogenesis in a beta-catenin-dependent manner
Q39684133	Cell delivery of Met docking site peptides inhibit angiogenesis and vascular tumor growth.
Q36497235	Cell growth, global phosphotyrosine elevation, and c-Met phosphorylation through Src family kinases in colorectal cancer cells
Q36844181	Cell motility and cytoskeletal regulation in invasion and metastasis
Q34077976	Cell motility dynamics: a novel segmentation algorithm to quantify multi-cellular bright field microscopy images.
Q62499594	Cell segmentation using front vector flow guided active contours
Q38125434	Cell-Autonomous and Non–Cell-Autonomous Mechanisms of HGF/MET–Driven Resistance to Targeted Therapies: From Basic Research to a Clinical Perspective
Q34564103	Cell-line-specific stimulation of tumor cell aggressiveness by wound healing factors – a central role for STAT3
Q28570139	Cellular mechanisms underlying the regulation of dendritic development by hepatocyte growth factor
Q47164059	Challenges and future of biomarker tests in the era of precision oncology: Can we rely on immunohistochemistry (IHC) or fluorescence in situ hybridization (FISH) to select the optimal patients for matched therapy?
Q37295179	Change in hepatocyte growth factor concentration promote mesenchymal stem cell‐mediated osteogenic regeneration
Q37890208	Changing Pathology with Changing Drugs: Tumors of the Gastrointestinal Tract
Q39183265	Changing the Therapeutic Landscape in Non-small Cell Lung Cancers: the Evolution of Comprehensive Molecular Profiling Improves Access to Therapy.
Q33893715	Characterization of a Human Cell Line Stably Over-Expressing the Candidate Oncogene, Dual Specificity Phosphatase 12
Q54501808	Characterization of the timing and prevalence of receptor tyrosine kinase expression changes in oesophageal carcinogenesis.
Q40419085	Characterization, expression and function of c-Met in canine spontaneous cancers
Q36669662	Cheminfomatic-based Drug Discovery of Human Tyrosine Kinase Inhibitors
Q34533693	Chromosomal amplification of leucine-rich repeat kinase-2 (LRRK2) is required for oncogenic MET signaling in papillary renal and thyroid carcinomas
Q58773054	Circulating Levels of Omentin, Leptin, VEGF, and HGF and Their Clinical Relevance with PSA Marker in Prostate Cancer
Q54448708	Circulating tumor cells: determining its number and what it means.
Q92079327	Clinical Implications and Translation of an Off-Target Pharmacology Profiling Hit: Adenosine Uptake Inhibition In Vitro
Q38979283	Clinical Pharmacokinetics and Pharmacodynamics of Cabozantinib
Q47616848	Clinical and prognostic value of the C-Met/HGF signaling pathway in cervical cancer
Q53221535	Clinical correlations and prognostic relevance of HGF, VEGF AND FGF expression in Brazilian patients with non-Hodgkin lymphoma.
Q43625604	Clinical impact of c-Met expression and its gene amplification in hepatocellular carcinoma
Q37690299	Clinical implications of MET gene copy number in lung cancer
Q26776190	Clinical significance of MET in gastric cancer
Q92151665	Clinicopathologic and Imaging Features of Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations
Q34483478	Co-expression of MET and CD47 is a novel prognosticator for survival of luminal breast cancer patients
Q38718726	Co-targeting HGF/cMET Signaling with MEK Inhibitors in Metastatic Uveal Melanoma
Q58730323	Combination of EGFR Inhibitor Lapatinib and MET Inhibitor Foretinib Inhibits Migration of Triple Negative Breast Cancer Cell Lines
Q39044577	Combined MET inhibition and topoisomerase I inhibition block cell growth of small cell lung cancer
Q91656784	Combined Treatment with MEK and mTOR Inhibitors is Effective in In Vitro and In Vivo Models of Hepatocellular Carcinoma
Q37148144	Combined hyperthermia and radiotherapy for the treatment of cancer
Q21245750	Combined targeting of mTOR and c-MET signaling pathways for effective management of epithelioid sarcoma
Q41601309	Comparison of the c-MET gene amplification between primary tumor and metastatic lymph nodes in non-small cell lung cancer
Q38864021	Comprehensive gene and microRNA expression profiling reveals miR-206 inhibits MET in lung cancer metastasis
Q33231241	Computer-assisted mass spectrometric analysis of naturally occurring and artificially introduced cross-links in proteins and protein complexes.
Q34595811	Conditional activation of MET in differentiated skeletal muscle induces atrophy.
Q35628589	Conditioned medium from umbilical cord mesenchymal stem cells induces migration and angiogenesis
Q37984807	Conflicting Roles of Molecules in Hepatocarcinogenesis: Paradigm or Paradox
Q26861688	Connexins, gap junctions and tissue invasion
Q34494731	Constitutive activation of MET signaling impairs myogenic differentiation of rhabdomyosarcoma and promotes its development and progression
Q31062741	Constitutively active c-Met kinase in PC-3 cells is autocrine-independent and can be blocked by the Met kinase inhibitor BMS-777607
Q33222167	Construction of human naïve Fab library and characterization of anti-met Fab fragment generated from the library
Q39268346	Construction, expression, and characterization of an anti-tumor immunotoxin containing the human anti-c-Met single-chain antibody and PE38KDEL
Q30422676	Cooperation between c-Met and Focal Adhesion Kinase Family Members in Medulloblastoma and Implications for Therapy
Q53187961	Copy number gain of PIK3CA and MET is associated with poor prognosis in head and neck squamous cell carcinoma.
Q39148397	Critical role of TRPC6 channels in the development of human renal cell carcinoma
Q37571068	Critical signal transduction pathways in CLL.
Q47122191	Crizotinib targets in glioblastoma stem cells.
Q51772134	Cross-talk between the VEGF-A and HGF signalling pathways in endothelial cells
Q36508899	Crosstalk between the alpha2beta1 integrin and c-met/HGF-R regulates innate immunity
Q24294589	Crystal structure of the HGF beta-chain in complex with the Sema domain of the Met receptor
Q42382997	Curcumin inhibited HGF-induced EMT and angiogenesis through regulating c-Met dependent PI3K/Akt/mTOR signaling pathways in lung cancer
Q35866113	Curcumin: Updated Molecular Mechanisms and Intervention Targets in Human Lung Cancer
Q89422561	Current Molecular-Targeted Therapies in NSCLC and Their Mechanism of Resistance
Q34310062	Current concepts on the molecular pathology of non-small cell lung carcinoma
Q87286269	Cyclooxygenase-2--An Imperative Prognostic Biomarker in Oral Squamous Cell Carcinoma--An Immunohistochemical Study
Q24606703	Cyr61 mediates hepatocyte growth factor-dependent tumor cell growth, migration, and Akt activation
Q38025499	Cytokines as regulators of proliferation and survival of healthy and malignant peripheral B cells
Q29617924	Cytokinesis failure generating tetraploids promotes tumorigenesis in p53-null cells
Q37417678	Cytoskeleton rearrangements during Listeria infection: clathrin and septins as new players in the game
Q37137050	Cytotoxic activity of tivantinib (ARQ 197) is not due solely to c-MET inhibition.
Q31099702	Daily administration of low molecular weight heparin increases Hepatocyte Growth Factor serum levels in gynaecological patients: pharmacokinetic parameters and clinical implications
Q34439113	Decorin antagonizes Met receptor activity and down-regulates {beta}-catenin and Myc levels
Q37263981	Decorin is a novel antagonistic ligand of the Met receptor
Q28268535	Decreased Serum Hepatocyte Growth Factor (HGF) in Autistic Children with Severe Gastrointestinal Disease
Q44324395	Degradation of the GAB1 adaptor by the ubiquitin–proteasome pathway hampers HGF/SF–MET signaling
Q34340834	Delphinidin inhibits cell proliferation and invasion via modulation of Met receptor phosphorylation
Q39690744	Demethylation of a LINE-1 antisense promoter in the cMet locus impairs Met signalling through induction of illegitimate transcription
Q51065441	Design Some New Type-I c-met Inhibitors Based on Molecular Docking and Topomer CoMFA Research.
Q35893861	Detection of MET Gene Copy Number in Cancer Samples Using the Droplet Digital PCR Method
Q36135757	Detection of MET and SOX2 amplification by quantitative real-time PCR in non-small cell lung carcinoma
Q39737497	Detection of circulating tumor cells in breast cancer patients utilizing multiparameter flow cytometry and assessment of the prognosis of patients in different CTCs levels
Q91559240	Detection of colonic neoplasia in vivo using near-infrared-labeled peptide targeting cMet
Q28743359	Detection of hepatocyte growth factor (HGF) ligand-c-MET receptor activation in formalin-fixed paraffin embedded specimens by a novel proximity assay
Q40868267	Determination of crizotinib in human and mouse plasma by liquid chromatography electrospray ionization-tandem mass spectrometry (LC-ESI-MS/MS).
Q30872503	Deubiquitinase activities required for hepatocyte growth factor-induced scattering of epithelial cells
Q46344608	Development of Angiotensin IV Analogs as Hepatocyte Growth Factor/Met Modifiers
Q39858627	Development of a cell-based assay for measurement of c-Met phosphorylation using AlphaScreen technology and high-content imaging analysis
Q38912279	Development of antibody-based c-Met inhibitors for targeted cancer therapy
Q34198905	Development of c-MET pathway inhibitors
Q48148598	Developmentally regulated signaling pathways in glioma invasion.
Q40075732	Diacylglycerol kinase-alpha mediates hepatocyte growth factor-induced epithelial cell scatter by regulating Rac activation and membrane ruffling.
Q39561871	Diacylglycerol kinases are essential for hepatocyte growth factor-dependent proliferation and motility of Kaposi's sarcoma cells
Q59339859	Different Fgfs have distinct roles in regulating neurogenesis after spinal cord injury in zebrafish
Q58748732	Differential responses of MET activations to MET kinase inhibitor and neutralizing antibody
Q38370754	Differential roles of trans-phosphorylated EGFR, HER2, HER3, and RET as heterodimerisation partners of MET in lung cancer with MET amplification
Q40416072	Differentiation of a mouse submandibular gland-derived cell line (SCA) grown on matrigel
Q41612212	Dimerization of EGFR and HER2 induces breast cancer cell motility through STAT1-dependent ACTA2 induction.
Q83903141	Diosgenin Suppresses Hepatocyte Growth Factor (HGF)-Induced Epithelial–Mesenchymal Transition by Down-regulation of Mdm2 and Vimentin
Q36487012	Direct binding of hepatocyte growth factor and vascular endothelial growth factor to CD44v6.
Q30445760	Direct interaction of focal adhesion kinase (FAK) with Met is required for FAK to promote hepatocyte growth factor-induced cell invasion
Q34080493	Discovering potent inhibitors against c-Met kinase: molecular design, organic synthesis and bioassay
Q27683894	Discovery of 1-[3-(1-Methyl-1H-pyrazol-4-yl)-5-oxo-5H-benzo[4,5]cyclohepta[1,2-b]pyridin-7-yl]-N-(pyridin-2-ylmethyl)methanesulfonamide (MK-8033): A Specific c-Met/Ron Dual Kinase Inhibitor with Preferential Affinity for the Activated State of c-Met
Q39348879	Discovery of 3H‐Imidazo[4,5‐b]pyridines as Potent c‐Met Kinase Inhibitors: Design, Synthesis, and Biological Evaluation
Q27684390	Discovery of Anilinopyrimidines as Dual Inhibitors of c-Met and VEGFR-2: Synthesis, SAR, and Cellular Activity
Q34187026	Discovery of a 5H-Benzo[4,5]cyclohepta[1,2-b]pyridin-5-one (MK-2461) Inhibitor of c-Met Kinase for the Treatment of Cancer
Q39470365	Discovery of a Novel B-Raf Fusion Protein Related to c-Met Drug Resistance
Q36872149	Discovery of a new series of imidazo[1,2-a]pyridine compounds as selective c-Met inhibitors.
Q37133949	Discovery of fully human anti-MET monoclonal antibodies with antitumor activity against colon cancer tumor models in vivo
Q39302607	Discovery of novel 2-aminopyridine-3-carboxamides as c-Met kinase inhibitors
Q39158608	Discovery of novel 4-(2-fluorophenoxy)quinoline derivatives bearing 4-oxo-1,4-dihydrocinnoline-3-carboxamide moiety as c-Met kinase inhibitors
Q39021161	Discovery of novel c-Met inhibitors bearing a 3-carboxyl piperidin-2-one scaffold.
Q87014664	Dismantling papillary renal cell carcinoma classification: The heterogeneity of genetic profiles suggests several independent diseases
Q57283460	Disruption of MET receptor tyrosine kinase, an autism risk factor, impairs developmental synaptic plasticity in the hippocampus
Q38652468	Distinct projection targets define subpopulations of mouse brainstem vagal neurons that express the autism-associated MET receptor tyrosine kinase
Q43158611	Distinct recruitment of Eps15 via Its coiled-coil domain is required for efficient down-regulation of the met receptor tyrosine kinase
Q30480183	Distinct requirements for Gab1 in Met and EGF receptor signaling in vivo
Q90241222	Distinguishing Between Monomeric scFv and Diabody in Solution Using Light and Small Angle X-ray Scattering
Q55459483	Dock1 promotes the mesenchymal transition of glioma and is modulated by MiR-31.
Q37697193	Does hepatocyte growth factor/c-Met signal play synergetic role in lung cancer?
Q37175416	Down-regulation of the met receptor tyrosine kinase by presenilin-dependent regulated intramembrane proteolysis
Q29010479	Drug development against metastasis-related genes and their pathways: A rationale for cancer therapy
Q34782774	Drug development of MET inhibitors: targeting oncogene addiction and expedience
Q35110418	Dual Blockade of EGFR and c-Met Abrogates Redundant Signaling and Proliferation in Head and Neck Carcinoma Cells
Q42282846	Dual Constant Domain-Fab: A novel strategy to improve half-life and potency of a Met therapeutic antibody.
Q36882696	Dual MET-EGFR combinatorial inhibition against T790M-EGFR-mediated erlotinib-resistant lung cancer.
Q38751892	Dual MET/EGFR therapy leads to complete response and resistance prevention in a MET-amplified gastroesophageal xenopatient cohort
Q98293097	Dual Targeting of VEGFR2 and C-Met Kinases via the Design and Synthesis of Substituted 3-(Triazolo-thiadiazin-3-yl)indolin-2-one Derivatives as Angiogenesis Inhibitors
Q34537725	Dual effects of a targeted small-molecule inhibitor (cabozantinib) on immune-mediated killing of tumor cells and immune tumor microenvironment permissiveness when combined with a cancer vaccine
Q27851725	Durable complete response of metastatic gastric cancer with anti-Met therapy followed by resistance at recurrence
Q39001792	Dynamic reprogramming of signaling upon met inhibition reveals a mechanism of drug resistance in gastric cancer
Q26799900	Dysregulation of the Met pathway in non-small cell lung cancer: implications for drug targeting and resistance
Q34088774	E-cadherin as an indicator of mesenchymal to epithelial reverting transitions during the metastatic seeding of disseminated carcinomas.
Q49571137	EGFR and AKT1 overexpression are mutually exclusive and associated with a poor survival in resected gastric adenocarcinomas.
Q24338635	EGFR/Met association regulates EGFR TKI resistance in breast cancer
Q99711697	EGFR/c-Met and mTOR signaling are predictors of survival in non-small cell lung cancer
Q33756853	EGFRvIII and c-Met pathway inhibitors synergize against PTEN-null/EGFRvIII+ glioblastoma xenografts.
Q39171903	EMD 1214063 and EMD 1204831 Constitute a New Class of Potent and Highly Selective c-Met Inhibitors
Q39233875	EMT, CSCs, and drug resistance: the mechanistic link and clinical implications
Q37355527	ETS2 Mediated Tumor Suppressive Function and MET Oncogene Inhibition in Human Non–Small Cell Lung Cancer
Q35584967	Early clinical development of ARQ 197, a selective, non-ATP-competitive inhibitor targeting MET tyrosine kinase for the treatment of advanced cancers.
Q39815105	Ectodomain shedding of E-cadherin and c-Met is induced by Helicobacter pylori infection
Q36955645	Effect of YAP1 silencing on esophageal cancer
Q38774306	Effect of brefelamide on HGF-induced survival of 1321N1 human astrocytoma cells
Q41911192	Effects of CpG methylation on recognition of DNA by the tumour suppressor p53.
Q43684978	Effects of MACC1 siRNA on biological behaviors of HeLa
Q39039219	Effects of Tea Catechins on Cancer Signaling Pathways
Q34381481	Effects of a green tea extract, Polyphenon E, on systemic biomarkers of growth factor signalling in women with hormone receptor-negative breast cancer
Q21284409	Effects of simulated altitude (normobaric hypoxia) on cardiorespiratory parameters and circulating endothelial precursors in healthy subjects
Q39713503	Effects of transferred NK4 gene on proliferation, migration, invasion and apoptosis of human prostate cancer DU145 cells
Q61813445	Efficient Selection of Antibodies Reactive to Homologous Epitopes on Human and Mouse Hepatocyte Growth Factors by Next-Generation Sequencing-Based Analysis of the B Cell Repertoire
Q38801405	Elevated hepatocyte growth factor expression as an autocrine c-Met activation mechanism in acquired resistance to sorafenib in hepatocellular carcinoma cells
Q37137157	Elevated serum concentrations of activated hepatocyte growth factor activator in patients with multiple myeloma
Q37536730	Ellagitannin-rich cloudberry inhibits hepatocyte growth factor induced cell migration and phosphatidylinositol 3-kinase/AKT activation in colon carcinoma cells and tumors in Min mice
Q34412684	Emergence of HGF/SF-induced coordinated cellular motility
Q38706872	Emergence of MET hyper-amplification at progression to MET and BRAF inhibition in colorectal cancer
Q35999255	Emerging Targeted Therapies for Castration-Resistant Prostate Cancer
Q37723147	Emerging anticancer therapeutic targets and the cardiovascular system: is there cause for concern?
Q38506084	Emerging kinase inhibitors of the treatment of gastric cancer
Q36764016	Emerging monoclonal antibody therapies for malignant gliomas
Q38485779	Emerging tyrosine kinase inhibitors for the treatment of renal cancer
Q39431959	Endocan in Cancers: A Lesson from a Circulating Dermatan Sulfate Proteoglycan
Q37537921	Endocytosis and spatial restriction of cell signaling
Q39026766	Endometrial Carcinoma: Specific Targeted Pathways.
Q33551889	Energetic factors determining the binding of type I inhibitors to c-Met kinase: experimental studies and quantum mechanical calculations
Q27671505	Engineered variants of InlB with an additional leucine‐rich repeat discriminate between physiologically relevant and packing contacts in crystal structures of the InlB:MET complex
Q33970874	Engineering hepatocyte growth factor fragments with high stability and activity as Met receptor agonists and antagonists
Q34077651	Enhanced activity of meprin-α, a pro-migratory and pro-angiogenic protease, in colorectal cancer
Q48196960	Enhanced expression and phosphorylation of the MET oncoprotein by glioma-specific PTPRZ1-MET fusions.
Q45143177	Enhanced growth of human met-expressing xenografts in a new strain of immunocompromised mice transgenic for human hepatocyte growth factor/scatter factor
Q24294625	Enhanced prediction of Src homology 2 (SH2) domain binding potentials using a fluorescence polarization-derived c-Met, c-Kit, ErbB, and androgen receptor interactome
Q36526600	Entry of Listeria monocytogenes in Mammalian Epithelial Cells: An Updated View
Q36785885	Entry of the bacterial pathogen Listeria monocytogenes into mammalian cells
Q29619988	Eph receptor signalling casts a wide net on cell behaviour
Q38079335	Epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of NSCLC
Q35956303	Epigenetic Silencing of SPINT2 Promotes Cancer Cell Motility via HGF-MET Pathway Activation in Melanoma
Q42089246	Epithelial Tumor, Invasion and Stroma
Q41835409	Epithelial-Mesenchymal Transition Induced by Senescent Fibroblasts
Q37621666	Epithelial-mesenchymal Transition---A Hallmark of Breast Cancer Metastasis
Q36986452	Epithelial-mesenchymal transition in breast cancer progression and metastasis
Q39461023	Epithelial-mesenchymal transition in malignant mesothelioma
Q38885876	Erk2 but not Erk1 regulates crosstalk between Met and EGFR in squamous cell carcinoma cell lines
Q36605522	Erlotinib Resistance in Lung Cancer: Current Progress and Future Perspectives
Q42700668	Erlotinib-based doublet targeted therapy versus erlotinib alone in previously treated advanced non-small-cell lung cancer: a meta-analysis from 24 randomized controlled trials
Q24561624	Essential role of BCL9-2 in the switch between beta-catenin's adhesive and transcriptional functions
Q37399540	Ethnic differences and functional analysis of MET mutations in lung cancer
Q39186427	Evaluation of the antitumor effects of rilotumumab by PET imaging in a U-87 MG mouse xenograft model
Q41108912	Evaluation of tyrosine kinase receptors in brain metastases of clear cell renal cell carcinoma reveals cMet as a negative prognostic factor
Q43188119	Evidence for LKB1/AMP-activated protein kinase/ endothelial nitric oxide synthase cascade regulated by hepatocyte growth factor, S-adenosylmethionine, and nitric oxide in hepatocyte proliferation.
Q28250282	Evidence that MIG-6 is a tumor-suppressor gene
Q38735120	Exon 14 Deleted MET Receptor as a New Biomarker and Target in Cancers.
Q92059907	Exosome-Delivered c-Met siRNA Could Reverse Chemoresistance to Cisplatin in Gastric Cancer
Q37645086	Exosomes: small vesicles with big roles in hepatocellular carcinoma
Q57360231	Exploring the chemical space of the lysine-binding pocket of the first kringle domain of hepatocyte growth factor/scatter factor (HGF/SF) yields a new class of inhibitors of HGF/SF-MET binding
Q36318551	Exploring the tumour environment: cancer-associated fibroblasts as targets in cancer therapy
Q35677873	Exposure-response analysis of rilotumumab in gastric cancer: the role of tumour MET expression
Q54645357	Expression and Prognostic Significance of CD151, c-Met, and Integrin alpha3/alpha6 in Pancreatic Ductal Adenocarcinoma
Q37209597	Expression and prognostic relevance of MET and phospho-BAD in non-small cell lung cancer
Q33688558	Expression of MET in circulating tumor cells correlates with expression in tumor tissue from advanced-stage lung cancer patients
Q31121236	Expression of ST3GAL4 Leads to SLex Expression and Induces c-Met Activation and an Invasive Phenotype in Gastric Carcinoma Cells
Q36518737	Expression of c-Met Is Different along the Location and Associated with Lymph Node Metastasis of Head and Neck Carcinoma
Q39868710	Expression of hepatocyte growth factor and its receptor met in Wilms' tumors and nephrogenic rests reflects their roles in kidney development
Q47834432	Expression of hepatocyte growth factor and the proto-oncogenic receptor c-Met in canine osteosarcoma
Q45330358	Expression of the Hepatocyte Growth Factor and C-Met in Colon Cancer: Correlation with Clinicopathological Features and Overall Survival
Q35944671	Expression of the c-Met oncogene by tumor cells predicts a favorable outcome in classical Hodgkin's lymphoma
Q57791826	Extracellular Matrix Influencing HGF/c-MET Signaling Pathway: Impact on Cancer Progression
Q36026812	Extravillous trophoblast and decidual natural killer cells: a remodelling partnership.
Q47360764	Ezrin mediates both HGF/Met autocrine and non-autocrine signaling-induced metastasis in melanoma
Q35681312	Ezrin...a metastatic detERMinant?
Q53058993	FN14 expression correlates with MET in NSCLC and promotes MET-driven cell invasion.
Q38941681	FOXC2 promotes colorectal cancer metastasis by directly targeting MET.
Q30568524	Fell-Muir Lecture: Heparan sulphate and the art of cell regulation: a polymer chain conducts the protein orchestra
Q28483012	Fenton reaction induced cancer in wild type rats recapitulates genomic alterations observed in human cancer
Q28258147	Fibroblast nemosis arrests growth and induces differentiation of human leukemia cells
Q39771894	Fibroblast nemosis induces angiogenic responses of endothelial cells
Q46082233	Filamin a mediates HGF/c-MET signaling in tumor cell migration
Q92127485	First-in-Human Phase I Study of Merestinib, an Oral Multikinase Inhibitor, in Patients with Advanced Cancer
Q36501662	Flexibility and small pockets at protein-protein interfaces: New insights into druggability.
Q27667030	Fold and Function of the InlB B-repeat
Q35203637	Foretinib (GSK1363089), an orally available multikinase inhibitor of c-Met and VEGFR-2, blocks proliferation, induces anoikis, and impairs ovarian cancer metastasis.
Q38081379	Foretinib (XL880): c-MET Inhibitor with Activity in Papillary Renal Cell Cancer
Q39424703	Foretinib demonstrates anti-tumor activity and improves overall survival in preclinical models of hepatocellular carcinoma.
Q30581656	Four individually druggable MET hotspots mediate HGF-driven tumor progression.
Q36745364	From Tpr-Met to Met, tumorigenesis and tubes.
Q42912698	Frzb, a secreted Wnt antagonist, decreases growth and invasiveness of fibrosarcoma cells associated with inhibition of Met signaling
Q21245511	Function, regulation and pathological roles of the Gab/DOS docking proteins
Q36559844	Functional role of glycosphingolipids and gangliosides in control of cell adhesion, motility, and growth, through glycosynaptic microdomains
Q39405818	Future directions in the evaluation of c-MET-driven malignancies
Q35072671	GD3 synthase regulates epithelial-mesenchymal transition and metastasis in breast cancer.
Q34726188	GEP100 links epidermal growth factor receptor signalling to Arf6 activation to induce breast cancer invasion.
Q42758493	GGA3 functions as a switch to promote Met receptor recycling, essential for sustained ERK and cell migration
Q38329139	GM3 and cancer
Q43200145	Gab Docking Proteins in Cardiovascular Disease, Cancer, and Inflammation
Q35010265	Gab1 is required for cell cycle transition, cell proliferation, and transformation induced by an oncogenic met receptor.
Q39545863	Ganglioside GD1a negatively regulates hepatocyte growth factor expression through caveolin-1 at the transcriptional level in murine osteosarcoma cells
Q35625349	Gastric cancer and the epoch of immunotherapy approaches
Q28570307	Gastrointestinal hormones cause rapid c-Met receptor down-regulation by a novel mechanism involving clathrin-mediated endocytosis and a lysosome-dependent mechanism
Q40443951	Geldanamycins exquisitely inhibit HGF/SF-mediated tumor cell invasion
Q83818621	Gene amplification and protein overexpression of MET are common events in ovarian clear-cell adenocarcinoma: their roles in tumor progression and prognostication of the patient
Q38698722	Gene expression profiles and signaling mechanisms in α2B-adrenoceptor-evoked proliferation of vascular smooth muscle cells
Q41976129	Gene network dynamics controlling keratinocyte migration
Q38490458	Gene of the month: MET.
Q39159155	Gene silencing of c-Met leads to brain metastasis inhibitory effects
Q36115735	Genetic Changes in Squamous Cell Lung Cancer: A Review
Q24675200	Genetic targeting of the kinase activity of the Met receptor in cancer cells
Q37452220	Genetically modified animal models recapitulating molecular events altered in human hepatocarcinogenesis
Q38050092	Genomic dysregulation in gastric tumors
Q96610153	Genomic profiling in renal cell carcinoma
Q36072027	Genomic profiling of a Hepatocyte growth factor-dependent signature for MET-targeted therapy in glioblastoma
Q33737789	Germline Met Mutations in Mice Reveal Mutation- and Background-Associated Differences in Tumor Profiles
Q39647403	Glioblastoma Resistance to Anti-VEGF Therapy: Has the Challenge Been MET?
Q37061805	Glioma surgical aspirate: a viable source of tumor tissue for experimental research
Q39698371	Glycoprotein production for structure analysis with stable, glycosylation mutant CHO cell lines established by fluorescence-activated cell sorting.
Q38008271	Glycosaminoglycan and Chemokine/Growth Factor Interactions
Q58199697	Grb2 signaling in cell motility and cancer
Q37798221	Green tea and cancer prevention
Q37774602	Growth factor signaling pathways as targets for prevention of epithelial carcinogenesis.
Q42379051	Growth factor- and cytokine-driven pathways governing liver stemness and differentiation
Q37045217	Growth factors and oncogenes as targets in melanoma: lost in translation?
Q24532853	Growth factors induce differential phosphorylation profiles of the Hrs-STAM complex: a common node in signalling networks with signal-specific properties
Q37632169	Guanine nucleotide exchange factor Dock7 mediates HGF-induced glioblastoma cell invasion via Rac activation
Q35174872	HGF and c-Met participate in paracrine tumorigenic pathways in head and neck squamous cell cancer
Q39263953	HGF induces novel EGFR functions involved in resistance formation to tyrosine kinase inhibitors
Q43876212	HGF regulates VEGF expression via the c-Met receptor downstream pathways, PI3K/Akt, MAPK and STAT3, in CT26 murine cells
Q34550898	HGF rescues colorectal cancer cells from EGFR inhibition via MET activation
Q37488181	HGF signaling regulates Claudin-3 dynamics through its C-terminal tyrosine residues
Q36966973	HGF-MET signals via the MLL-ETS2 complex in hepatocellular carcinoma
Q37104714	HGF-independent regulation of MET and GAB1 by nonreceptor tyrosine kinase FER potentiates metastasis in ovarian cancer
Q57022052	HGF-induced formation of the MET-AXL-ELMO2-DOCK180 complex promotes RAC1 activation, receptor clustering, and cancer cell migration and invasion
Q39730212	HGF-induced invasion by prostate tumor cells requires anterograde lysosome trafficking and activity of Na+-H+ exchangers
Q39720254	HGF-promoted motility in primary human melanocytes depends on CD44v6 regulated via NF-kappa B, Egr-1, and C/EBP-beta
Q38883827	HGF/Met Signaling in Head and Neck Cancer: Impact on the Tumor Microenvironment.
Q39819780	HGF/Met signalling promotes PGE(2) biogenesis via regulation of COX-2 and 15-PGDH expression in colorectal cancer cells
Q55009988	HGF/Met-Signaling Contributes to Immune Regulation by Modulating Tolerogenic and Motogenic Properties of Dendritic Cells.
Q30501481	HGF/SF increases tumor blood volume: a novel tool for the in vivo functional molecular imaging of Met.
Q36027374	HGF/SF-Met signaling in tumor progression
Q51152435	HGF/c-MET Axis in Tumor Microenvironment and Metastasis Formation.
Q42819341	HGF/c-Met Acts as an Alternative Angiogenic Pathway in Sunitinib-Resistant Tumors
Q93028374	HGF/c-Met Promote Renal Carcinoma Cancer Stem Cells Enrichment Through Upregulation of Cir-CCDC66
Q38397298	HGF/c-met system targeting PI3K/AKT and STAT3/phosphorylated-STAT3 pathways in pituitary adenomas: an immunohistochemical characterization in view of targeted therapies.
Q36574446	HIF-1α Overexpression Induces Angiogenesis in Mesenchymal Stem Cells
Q54245240	HSP27 is required for invasion and metastasis triggered by hepatocyte growth factor.
Q39608945	Head neck squamous cell carcinoma c‐Met+ cells display cancer stem cell properties and are responsible for cisplatin‐resistance and metastasis
Q37204035	Helicobacter pylori induces cancer cell motility independent of the c-Met receptor
Q42370129	Hematopoietic Stem Cell-derived Adipocytes Promote Tumor Growth and Cancer Cell Migration
Q34675956	Heparanase Plays a Dual Role in Driving Hepatocyte Growth Factor (HGF) Signaling by Enhancing HGF Expression and Activity
Q34802739	Hepatic differentiation of human bone marrow-derived mesenchymal stem cells by tetracycline-regulated hepatocyte nuclear factor 3beta
Q36957055	Hepatic stellate cell promoted hepatoma cell invasion via the HGF/c-Met signaling pathway regulated by p53
Q38866174	Hepatocellular carcinoma-derived exosomes promote motility of immortalized hepatocyte through transfer of oncogenic proteins and RNAs.
Q92531037	Hepatocyte Growth Factor Receptor overexpression predicts reduced survival but its targeting is not effective in unselected HNSCC patients
Q26781273	Hepatocyte Growth Factor from a Clinical Perspective: A Pancreatic Cancer Challenge
Q33607965	Hepatocyte Growth Factor/c-Met Signaling in Head and Neck Cancer and Implications for Treatment
Q61795626	Hepatocyte Growth Factor: A Microenvironmental Resource for Leukemic Cell Growth
Q35673676	Hepatocyte growth factor (HGF) autocrine activation predicts sensitivity to MET inhibition in glioblastoma
Q39195929	Hepatocyte growth factor activates tumor stromal fibroblasts to promote tumorigenesis in gastric cancer
Q28593159	Hepatocyte growth factor activator inhibitor-1 (HAI-1) is essential for the integrity of basement membranes in the developing placental labyrinth
Q28570356	Hepatocyte growth factor and c-Met promote dendritic maturation during hippocampal neuron differentiation via the Akt pathway
Q41893732	Hepatocyte growth factor and sonic Hedgehog expression in cerebellar neural progenitor cells costimulate medulloblastoma initiation and growth
Q40383250	Hepatocyte growth factor enhances CXCR4 expression favoring breast cancer cell invasiveness.
Q30851343	Hepatocyte growth factor enhances death receptor-induced apoptosis by up-regulating DR5
Q34972866	Hepatocyte growth factor induces cell scattering through MAPK/Egr-1-mediated upregulation of Snail
Q36248725	Hepatocyte growth factor induces epithelial cell motility through transactivation of the epidermal growth factor receptor
Q36547939	Hepatocyte growth factor inhibition: a novel therapeutic approach in pancreatic cancer
Q31161402	Hepatocyte growth factor is a preferred in vitro substrate for human hepsin, a membrane-anchored serine protease implicated in prostate and ovarian cancers
Q33919993	Hepatocyte growth factor promotes lymphatic vessel formation and function
Q43291021	Hepatocyte growth factor protects endothelial progenitor cell from damage of low-density lipoprotein cholesterol via the PI3K/Akt signaling pathway
Q40098619	Hepatocyte growth factor receptor c-MET is associated with FAS and when activated enhances drug-induced apoptosis in pediatric B acute lymphoblastic leukemia with TEL-AML1 translocation
Q34917042	Hepatocyte growth factor signaling in intrapancreatic ductal cells drives pancreatic morphogenesis
Q46959826	Hepatocyte growth factor signaling pathway inhibits cholesterol 7alpha-hydroxylase and bile acid synthesis in human hepatocytes
Q36840751	Hepatocyte growth factor/Met gene transfer in cardiac stem cells--potential for cardiac repair
Q83409298	Hepatocyte growth factor: Molecular biomarker and player in cardioprotection and cardiovascular regeneration
Q27863809	Hepsin activates pro-hepatocyte growth factor and is inhibited by hepatocyte growth factor activator inhibitor-1B (HAI-1B) and HAI-2.
Q45216230	Hereditary renal cell carcinomas
Q46227413	Hgf/c-met expression and functional analysis during zebrafish embryogenesis
Q36646078	High MET gene copy number predicted poor prognosis in primary intestinal diffuse large B-cell lymphoma
Q42414387	High c-MET expression is frequent but not associated with early PSA recurrence in prostate cancer
Q24681915	High expression of tumor endothelial marker 7 is associated with metastasis and poor survival of patients with osteogenic sarcoma
Q34277757	Histone Deacetylases Activate Hepatocyte Growth Factor Signaling by Repressing MicroRNA-449 in Hepatocellular Carcinoma Cells
Q36239069	Hormone-refractory prostate cancer in the Lobund-Wistar rat.
Q30160334	Host adaptor proteins Gab1 and CrkII promote InlB-dependent entry of Listeria monocytogenes
Q33762682	Hsa-miR-574-5p negatively regulates MACC-1 expression to suppress colorectal cancer liver metastasis
Q35777287	Human Cardiac Progenitor Spheroids Exhibit Enhanced Engraftment Potential.
Q41900240	Human DESC1 serine protease confers tumorigenic properties to MDCK cells and it is upregulated in tumours of different origin
Q41830301	Human platelets inhibit liver fibrosis in severe combined immunodeficiency mice
Q92242780	Humanized Anti-hepatocyte Growth Factor Monoclonal Antibody (YYB-101) Inhibits Ovarian Cancer Progression
Q36414376	Humanized anti-hepatocyte growth factor (HGF) antibody suppresses innate irinotecan (CPT-11) resistance induced by fibroblast-derived HGF.
Q30981767	Hypomethylation of a LINE-1 promoter activates an alternate transcript of the MET oncogene in bladders with cancer
Q55285319	Hypoxia leads to decreased autophosphorylation of the MET receptor but promotes its resistance to tyrosine kinase inhibitors.
Q90669561	Icotinib-resistant HCC827 cells produce exosomes with mRNA MET oncogenes and mediate the migration and invasion of NSCLC
Q53689233	Identification of a MET-eIF4G1 translational regulation axis that controls HIF-1α levels under hypoxia.
Q42801171	Identification of a novel germline MET mutation in dogs.
Q89231936	Identification of genomic and molecular traits that present therapeutic vulnerability to HGF-targeted therapy in glioblastoma
Q24645410	Identification of the receptor tyrosine kinase c-Met and its ligand, hepatocyte growth factor, as therapeutic targets in clear cell sarcoma
Q54976417	Imaging c-Met expression using 18F-labeled binding peptide in human cancer xenografts.
Q40104775	Imaging haematopoietic cells recruitment to an acute wound in vivo identifies a role for c-Met signalling
Q38707061	Imaging the Met Receptor Tyrosine Kinase (Met) and Assessing Tumor Responses to a Met Tyrosine Kinase Inhibitor in Human Xenograft Mouse Models with a [99mTc] (AH-113018) or CY 5** (AH-112543) Labeled Peptide
Q37696629	Immuno-PET of the hepatocyte growth factor receptor Met using the 1-armed antibody onartuzumab
Q43483788	Immunohistochemical analysis of hepatocyte growth factor and c-Met in plasma cell disease
Q53878549	Immunohistochemical application of a highly sensitive and specific murine monoclonal antibody recognising the extracellular domain of the human hepatocyte growth factor receptor (MET).
Q35770249	Immunohistochemical markers of prognosis in non-small cell lung cancer: a review and proposal for a multiphase approach to marker evaluation
Q37939411	Immunomodulatory properties of mesenchymal stem cells: cytokines and factors.
Q92714485	Immunostaining by dual tumor tissue paraffin blocks increases the sensitivity of c-Met detection in gastric cancer
Q55362851	Immunotherapies: Exploiting the Immune System for Cancer Treatment.
Q36075407	Impact of MET targeting on tumor-associated angiogenesis and growth of MET mutations-driven models of liver cancer
Q37272247	Impact of heat-shock protein 90 on cancer metastasis
Q52035790	Impact of laparotomy and liver resection on the peritoneal concentrations of fibroblast growth factor 2, vascular endothelial growth factor and hepatocyte growth factor
Q39404792	Impact of the small molecule Met inhibitor BMS-777607 on the metastatic process in a rodent tumor model with constitutive c-Met activation
Q36935015	Impact of tumor microenvironment and epithelial phenotypes on metabolism in breast cancer
Q35896530	Improved diagnostics targeting c-MET in non-small cell lung cancer: expression, amplification and activation?
Q42726359	Improvement in oral bioavailability of 2,4-diaminopyrimidine c-Met inhibitors by incorporation of a 3-amidobenzazepin-2-one group
Q37403891	In Vitro and In Vivo Activity of Cabozantinib (XL184), an Inhibitor of RET, MET, and VEGFR2, in a Model of Medullary Thyroid Cancer
Q51089746	In bone metastasis miR-34a-5p absence inversely correlates with Met expression, while Met oncogene is unaffected by miR-34a-5p in non-metastatic and metastatic breast carcinomas
Q39405780	In the clinic: ongoing clinical trials evaluating c-MET-inhibiting drugs
Q35070072	In vivo direct molecular imaging of early tumorigenesis and malignant progression induced by transgenic expression of GFP-Met
Q30010142	In vivo imaging of colorectal cancer growth and metastasis by targeting MACC1 with shRNA in xenografted mice
Q35325715	In-depth proteomic analysis of six types of exudative pleural effusions for nonsmall cell lung cancer biomarker discovery.
Q97569924	Incidence and PD-L1 Expression of MET 14 Skipping in Chinese Population: A Non-Selective NSCLC Cohort Study Using RNA-Based Sequencing
Q38976616	Increase of MET gene copy number confers resistance to a monovalent MET antibody and establishes drug dependence
Q35926926	Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients
Q39834676	Increased engraftment of hepatic progenitors after activation of the hepatocyte growth factor signaling pathway by protein transduction
Q35681957	Indole-3-carbinol synergistically sensitises ovarian cancer cells to bortezomib treatment
Q61796369	Induction of MET Receptor Tyrosine Kinase Down-regulation through Antibody-mediated Receptor Clustering
Q82062777	Inhibition of MET Receptor Tyrosine Kinase and Its Ligand Hepatocyte Growth Factor
Q40203442	Inhibition of c-Met as a therapeutic strategy for esophageal adenocarcinoma
Q37341925	Inhibition of fatty acid synthase by luteolin post-transcriptionally down-regulates c-Met expression independent of proteosomal/lysosomal degradation
Q38859217	Inhibition of ligand-independent constitutive activation of the Met oncogenic receptor by the engineered chemically-modified antibody DN30.
Q33901521	Inhibition of phosphorylated c-Met in rhabdomyosarcoma cell lines by a small molecule inhibitor SU11274
Q34398276	Inhibition of the MET Receptor Tyrosine Kinase as a Novel Therapeutic Strategy in Medulloblastoma
Q39000276	Inhibition of transforming growth factor-β signaling potentiates tumor cell invasion into collagen matrix induced by fibroblast-derived hepatocyte growth factor.
Q40322552	Inhibition of tumor growth and metastasis in vitro and in vivo by targeting macrophage migration inhibitory factor in human neuroblastoma.
Q40181511	Inhibitor of heat-shock protein 90 enhances the antitumor effect of DNA vaccine targeting clients of heat-shock protein.
Q40221705	Inhibitory effect of c-Met mutants on the formation of branching tubules by a porcine aortic endothelial cell line
Q50951740	Insight into the key features for ligand binding in Y1230 mutated c-Met kinase domain by molecular dynamics simulations
Q57009749	Integration of protein phosphorylation, acetylation, and methylation data sets to outline lung cancer signaling networks
Q36483438	Integration of transforming growth factor beta and RAS signaling silences a RAB5 guanine nucleotide exchange factor and enhances growth factor-directed cell migration
Q24677103	Integrin alpha 11 regulates IGF2 expression in fibroblasts to enhance tumorigenicity of human non-small-cell lung cancer cells
Q30443410	Integrin-dependent actomyosin contraction regulates epithelial cell scattering.
Q30437740	Interactions between PTEN and receptor tyrosine kinase pathways and their implications for glioma therapy
Q46835307	Interactions of hepatocyte growth factor/scatter factor with various glycosaminoglycans reveal an important interplay between the presence of iduronate and sulfate density.
Q50073141	Interleukin-1 receptor antagonist inhibits angiogenesis via blockage IL-1α/PI3K/NF-κβ pathway in human colon cancer cell
Q33361045	Interlobular and intralobular mammary stroma: genotype may not reflect phenotype
Q34971882	Interplay Between HGF/SF-Met-Ras Signaling, Tumor Metabolism and Blood Flow as a Potential Target for Breast Cancer Therapy
Q39503087	Intracellular signaling cascades triggered by the NK1 fragment of hepatocyte growth factor in human prostate epithelial cell line PNT1A
Q28253680	Invasive growth: a MET-driven genetic programme for cancer and stem cells
Q85827349	Inverse association between cancer risks and age in schizophrenic patients: a 12-year nationwide cohort study
Q90344379	Investigation of metastasis-associated in colon cancer-1 genetic variants in the development and clinicopathologcial characteristics of uterine cervical cancer in Taiwanese women
Q61852873	Involvement of HER-2/neu and metastasis-related proteins in the development of ileal neuroendocrine tumors
Q33529782	Involvement of PI3K and ERK1/2 pathways in hepatocyte growth factor-induced cholangiocarcinoma cell invasion
Q42911045	Isolation, characterization, and transplantation of cardiac endothelial cells.
Q40522198	JAM4 enhances hepatocyte growth factor-mediated branching and scattering of Madin-Darby canine kidney cells
Q39998605	KCNA1 and TRPC6 ion channels and NHE1 exchanger operate the biological outcome of HGF/scatter factor in renal tubular cells
Q39227712	Knockdown of MACC1 expression suppressed hepatocellular carcinoma cell migration and invasion and inhibited expression of MMP2 and MMP9
Q52318134	Known and novel roles of the MET oncogene in cancer: a coherent approach to targeted therapy.
Q24681561	LRIG1 is a novel negative regulator of the Met receptor and opposes Met and Her2 synergy
Q27675641	LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models
Q40092587	Lack of Fas antagonism by Met in human fatty liver disease
Q28586446	Laminin alpha1 globular domains 4-5 induce fetal development but are not vital for embryonic basement membrane assembly
Q46684257	Large-scale network models of IL-1 and IL-6 signalling and their hepatocellular specification
Q62559525	Leukocyte cell-derived chemotaxin 2 antagonizes MET receptor activation to suppress hepatocellular carcinoma vascular invasion by protein tyrosine phosphatase 1B recruitment
Q30430565	Ligand-independent activation of c-Met by fibronectin and α(5)β(1)-integrin regulates ovarian cancer invasion and metastasis
Q37018397	Ligand‐independent activation of MET through IGF‐1/IGF‐1R signaling
Q98499779	LncRNA TTN-AS1 promotes the progression of cholangiocarcinoma via the miR-320a/neuropilin-1 axis
Q50176288	Loss of Pten synergizes with c-Met to promote hepatocellular carcinoma development via mTORC2 pathway
Q33700482	Loss of c-Met disrupts gene expression program required for G2/M progression during liver regeneration in mice
Q34461690	Loss of glutathione peroxidase 3 expression is correlated with epigenetic mechanisms in endometrial adenocarcinoma
Q93062897	Lung Cancer Staging and Associated Genetic and Epigenetic Events
Q37147755	Lung adenocarcinoma: guiding EGFR-targeted therapy and beyond
Q37604947	MACC1 - more than metastasis? Facts and predictions about a novel gene.
Q42931083	MACC1 expression levels as a novel prognostic marker for colorectal cancer
Q39069991	MACC1 is involved in the regulation of proliferation, colony formation, invasion ability, cell cycle distribution, apoptosis and tumorigenicity by altering Akt signaling pathway in human osteosarcoma
Q90307966	MACC1 regulates PDL1 expression and tumor immunity through the c-Met/AKT/mTOR pathway in gastric cancer cells
Q30157439	MACC1, a newly identified key regulator of HGF-MET signaling, predicts colon cancer metastasis
Q36949256	MET Expression and Amplification in Patients with Localized Gastric Cancer
Q39327047	MET Increases the Sensitivity of Gefitinib-Resistant Cells to SN-38, an Active Metabolite of Irinotecan, by Up-Regulating the Topoisomerase I Activity
Q34972637	MET Inhibition Results in DNA Breaks and Synergistically Sensitizes Tumor Cells to DNA-Damaging Agents Potentially by Breaching a Damage-Induced Checkpoint Arrest
Q90227747	MET Inhibitors in Small Cell Lung Cancer: From the Bench to the Bedside
Q91789111	MET Oncogene in Non-Small Cell Lung Cancer: Mechanism of MET Dysregulation and Agents Targeting the HGF/c-Met Axis
Q48498498	MET Signaling Regulates Glioblastoma Stem Cells
Q37975092	MET Signaling: Novel Targeted Inhibition and Its Clinical Development in Lung Cancer
Q54729777	MET Y1253D-activating point mutation and development of distant metastasis in advanced head and neck cancers.
Q55491411	MET alterations detected in blood-derived circulating tumor DNA correlate with bone metastases and poor prognosis.
Q36984821	MET amplification as a potential therapeutic target in gastric cancer.
Q42317509	MET amplification in metastatic colorectal cancer: an acquired response to EGFR inhibition, not a de novo phenomenon
Q24646295	MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib
Q34257203	MET and AKT genetic influence on facial emotion perception
Q39130764	MET and ERBB2 Are Coexpressed in ERBB2+ Breast Cancer and Contribute to Innate Resistance
Q54439373	MET and MST1R as prognostic factors for classical Hodgkin's lymphoma
Q33926873	MET and MYC cooperate in mammary tumorigenesis
Q37232416	MET as a target for treatment of chest tumors
Q90306719	MET as resistance factor for afatinib therapy and motility driver in gastric cancer cells
Q37520331	MET exon 14 skipping defines a unique molecular class of non-small cell lung cancer
Q99400359	MET exon 14 skipping mutation, amplification and overexpression in pulmonary sarcomatoid carcinoma: A multi-center study
Q36140765	MET expression and copy number heterogeneity in nonsquamous non-small cell lung cancer (nsNSCLC).
Q37702041	MET expression and copy number status in clear-cell renal cell carcinoma: prognostic value and potential predictive marker
Q45839064	MET gain in diffuse astrocytomas is associated with poorer outcome
Q37490555	MET genetic abnormalities unreliable for patient selection for therapeutic intervention in oropharyngeal squamous cell carcinoma
Q37321772	MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients.
Q38390016	MET inhibition in lung cancer
Q26823203	MET inhibitors in combination with other therapies in non-small cell lung cancer
Q54277972	MET is a predictive factor for late recurrence but not for overall survival of early stage hepatocellular carcinoma
Q37427292	MET pathway as a therapeutic target
Q35208173	MET phosphorylation predicts poor outcome in small cell lung carcinoma and its inhibition blocks HGF-induced effects in MET mutant cell lines
Q35832923	MET receptor is a potential therapeutic target in high grade cervical cancer
Q38167461	MET receptor tyrosine kinase as an autism genetic risk factor
Q37706900	MET receptor variant R970C favors calpain-dependent generation of a fragment promoting epithelial cell scattering
Q37811895	MET signalling: principles and functions in development, organ regeneration and cancer
Q37645240	MET targeted therapy for lung cancer: clinical development and future directions
Q89603062	MET targeting: time for a rematch
Q30394618	MET-activating Residues in the B-repeat of the Listeria monocytogenes Invasion Protein InlB.
Q35694610	MET-dependent cancer invasion may be preprogrammed by early alterations of p53-regulated feedforward loop and triggered by stromal cell-derived HGF.
Q38675350	MET-targeted therapy for gastric cancer: the importance of a biomarker-based strategy.
Q47393684	MET-targeting antibody (emibetuzumab) and kinase inhibitor (merestinib) as single agent or in combination in a cancer model bearing MET exon 14 skipping
Q60909538	MET/HGF Co-Targeting in Pancreatic Cancer: A Tool to Provide Insight into the Tumor/Stroma Crosstalk
Q36520263	MET/HGF Signaling Pathway in Ovarian Carcinoma: Clinical Implications and Future Direction
Q37735662	MET4 expression predicts poor prognosis of gastric cancers with Helicobacter pylori infection
Q27008925	MET: A Critical Player in Tumorigenesis and Therapeutic Target
Q38430194	MET: a new promising biomarker in non-small-cell lung carcinoma
Q38008247	MET: a promising anticancer therapeutic target
Q39121333	MET: roles in epithelial-mesenchymal transition and cancer stemness
Q39330842	MLK3 Regulates Paxillin Phosphorylation in Chemokine-Mediated Breast Cancer Cell Migration and Invasion to Drive Metastasis
Q92537377	MM-131, a bispecific anti-Met/EpCAM mAb, inhibits HGF-dependent and HGF-independent Met signaling through concurrent binding to EpCAM
Q47112808	MP0250, a VEGF and HGF neutralizing DARPin® molecule shows high anti-tumor efficacy in mouse xenograft and patient-derived tumor models.
Q38116308	MSP–RON signalling in cancer: pathogenesis and therapeutic potential
Q24651422	MTDH activation by 8q22 genomic gain promotes chemoresistance and metastasis of poor-prognosis breast cancer
Q36484469	MUC1 drives c-Met-dependent migration and scattering.
Q33369840	Magic-factor 1, a partial agonist of Met, induces muscle hypertrophy by protecting myogenic progenitors from apoptosis
Q35740253	Magnolin inhibits cell migration and invasion by targeting the ERKs/RSK2 signaling pathway
Q42099833	Major HGF-mediated regenerative pathways are similarly affected in human and canine cirrhosis
Q38882524	Malignancy of bladder cancer cells is enhanced by tumor-associated fibroblasts through a multifaceted cytokine-chemokine loop
Q47947817	Management of Atypical Renal Cell Carcinomas
Q41988197	Managing sarcoma: where have we come from and where are we going?
Q36503129	Mast cell and neutrophil peptidases attack an inactivation segment in hepatocyte growth factor to generate NK4-like antagonists
Q36180735	Mechanisms and Targets Involved in Dissemination of Ovarian Cancer
Q34085432	Mechanisms of HGF/Met signaling to Brk and Sam68 in breast cancer progression
Q24607424	Mechanistic evaluation of the novel HSP90 inhibitor NVP-AUY922 in adult and pediatric glioblastoma
Q37871562	Mechanistic issues concerning cancer prevention by tea catechins
Q29618139	Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET
Q40047495	Membrane dynamics of resting and internalin B-bound MET receptor tyrosine kinase studied by single-molecule tracking.
Q37828318	Mesenchymal cell proliferation and programmed cell death: key players in fibrogenesis and new targets for therapeutic intervention
Q33947318	Met activation in non-small cell lung cancer is associated with de novo resistance to EGFR inhibitors and the development of brain metastasis
Q37416083	Met amplification and tumor progression in Cdkn2a-deficient melanocytes
Q37392930	Met and its ligand HGF are associated with clinical outcome in breast cancer
Q33654173	Met degradation by SAIT301, a Met monoclonal antibody, reduces the invasion and migration of nasopharyngeal cancer cells via inhibition of EGR-1 expression
Q39911616	Met gene copy number predicts the prognosis for completely resected non-small cell lung cancer
Q34440764	Met identification on human platelets: role of hepatocyte growth factor in the modulation of platelet activation
Q26864988	Met in urological cancers
Q37293205	Met induces diverse mammary carcinomas in mice and is associated with human basal breast cancer.
Q27316936	Met kinetic signature derived from the response to HGF/SF in a cellular model predicts breast cancer patient survival
Q36987592	Met provides essential signals for liver regeneration
Q39920221	Met receptor tyrosine kinase degradation is altered in response to the leucine-rich repeat of the Listeria invasion protein internalin B.
Q30010161	Met receptor tyrosine kinase signals through a cortactin-Gab1 scaffold complex, to mediate invadopodia
Q39834780	Met receptor tyrosine kinase transactivation is involved in proteinase-activated receptor-2-mediated hepatocellular carcinoma cell invasion.
Q24606871	Met receptors induce Sam68-dependent cell migration by activation of alternate extracellular signal-regulated kinase family members
Q42505884	Met signaling regulates growth, repopulating potential and basal cell-fate commitment of mammary luminal progenitors: implications for basal-like breast cancer.
Q51987719	Met signals hepatocyte survival by preventing Fas-triggered FLIP degradation in a PI3k-Akt-dependent manner.
Q36747465	Met synergizes with p53 loss to induce mammary tumors that possess features of claudin-low breast cancer
Q30446159	Met-Independent Hepatocyte Growth Factor-mediated regulation of cell adhesion in human prostate cancer cells
Q39978520	Met-driven invasive growth involves transcriptional regulation of Arhgap12.
Q34619635	Met-regulated expression signature defines a subset of human hepatocellular carcinomas with poor prognosis and aggressive phenotype
Q34097397	Met/Hepatocyte growth factor receptor ubiquitination suppresses transformation and is required for Hrs phosphorylation
Q64232580	Metastasis in the wild: investigating metastasis in non-laboratory animals
Q37409629	Metastasis-Associated in Colon Cancer-1 Associates With Poor Prognosis and Promotes Cell Invasion and Angiogenesis in Human Cervical Cancer
Q39185898	Metastasis-associated in colon cancer-1 upregulation predicts a poor prognosis of gastric cancer, and promotes tumor cell proliferation and invasion
Q47281319	Metastatic squamous cell carcinoma cells that overexpress c-Met exhibit enhanced angiogenesis factor expression, scattering and metastasis in response to hepatocyte growth factor
Q39978074	Metron factor-1 prevents liver injury without promoting tumor growth and metastasis
Q37109724	MiR-206 inhibits HGF-induced epithelial-mesenchymal transition and angiogenesis in non-small cell lung cancer via c-Met /PI3k/Akt/mTOR pathway
Q53187302	MiR-221 and miR-26b Regulate Chemotactic Migration of MSCs Toward HGF Through Activation of Akt and FAK.
Q55069380	MiR-335 inhibits migration of breast cancer cells through targeting oncoprotein c-Met.
Q36020979	MiR-338-3p inhibits epithelial-mesenchymal transition in gastric cancer cells by targeting ZEB2 and MACC1/Met/Akt signaling
Q36347188	MiR-34c suppresses tumor growth and metastasis in nasopharyngeal carcinoma by targeting MET
Q39322020	MiR-410 regulates MET to influence the proliferation and invasion of glioma
Q61417351	MiRNAs in Malignant Melanoma
Q37361575	MicroRNA involvement in hepatocellular carcinoma
Q34412493	MicroRNA-1 in Cardiac Diseases and Cancers
Q24648202	MicroRNA-1/206 targets c-Met and inhibits rhabdomyosarcoma development
Q34493584	MicroRNA-124-3p inhibits cell migration and invasion in bladder cancer cells by targeting ROCK1.
Q39358880	MicroRNA-143 Targets MACC1 to Inhibit Cell Invasion and Migration in Colorectal cancer
Q36217971	MicroRNA-182 Suppresses HGF/SF-Induced Increases in Retinal Pigment Epithelial Cell Proliferation and Migration through Targeting c-Met
Q35694945	MicroRNA-206: Effective Inhibition of Gastric Cancer Progression through the c-Met Pathway
Q34211970	MicroRNA-34a Inhibits the Proliferation and Metastasis of Osteosarcoma Cells Both In Vitro and In Vivo
Q39448254	MicroRNA-34b functions as a potential tumor suppressor in endometrial serous adenocarcinoma.
Q37462436	MicroRNA-409-3p Inhibits Migration and Invasion of Bladder Cancer Cells via Targeting c-Met
Q34675280	MicroRNAs in liver cancer: a model for investigating pathogenesis and novel therapeutic approaches.
Q33568086	Microvesicles derived from human Wharton's jelly mesenchymal stem cells promote human renal cancer cell growth and aggressiveness through induction of hepatocyte growth factor
Q39380720	Migration induced by epidermal and hepatocyte growth factors in oral squamous carcinoma cells in vitro: role of MEK/ERK, p38 and PI‐3 kinase/Akt
Q84806879	Mimics of the Dimerization Domain of Hepatocyte Growth Factor Exhibit Anti-Met and Anticancer Activity
Q47559475	Minimal model of directed cell motility on patterned substrates
Q83599980	Minimally Invasive Colorectal Resection Is Associated With a Transient Increase in Plasma Hepatocyte Growth Factor Levels Early After Surgery for Colon Cancer
Q40358363	Mitogen-inducible gene 6 is an endogenous inhibitor of HGF/Met-induced cell migration and neurite growth
Q36339995	Modeling the Transitions between Collective and Solitary Migration Phenotypes in Cancer Metastasis
Q36828371	Modulation of c-Met signaling and cellular sensitivity to radiation: potential implications for therapy
Q35585465	Molecular Parameters of Head and Neck Cancer Metastasis
Q50423780	Molecular Regulation of Sprouting Angiogenesis
Q52349570	Molecular background of the regional lymph node metastasis of gastric cancer
Q37788246	Molecular biology of squamous cell carcinoma of the head and neck: relevance and therapeutic implications
Q30497814	Molecular dissection of the migrating posterior lateral line primordium during early development in zebrafish.
Q37950202	Molecular functions of syndecan-1 in disease.
Q45826769	Molecular genetic analysis of the hepatocyte growth factor/MET signaling pathway in pediatric medulloblastoma
Q36729562	Molecular heterogeneity of glioblastomas: does location matter?
Q42857509	Molecular markers as therapeutic targets in lung cancer
Q40234882	Molecular mechanism of adaphostin-mediated G1 arrest in prostate cancer (PC-3) cells: signaling events mediated by hepatocyte growth factor receptor, c-Met, and p38 MAPK pathways
Q37711135	Molecular mechanism of pancreatic cancer--understanding proliferation, invasion, and metastasis
Q37878879	Molecular mechanisms of cholangiocarcinoma
Q38156191	Molecular pathways and potential therapeutic targets in glioblastoma multiforme
Q36772562	Molecular predictors of EGFR-TKI sensitivity in advanced non-small cell lung cancer
Q37779804	Molecular targeted therapy of advanced hepatocellular carcinoma beyond sorafenib
Q37690149	Molecular targeting of hepatocyte growth factor by an antagonist, NK4, in the treatment of rheumatoid arthritis
Q38267142	Molecular targets in the treatment of non-small-cell lung cancer: is there hope on the horizon?
Q42151322	Molecular therapy targeting Sonic hedgehog and hepatocyte growth factor signaling in a mouse model of medulloblastoma
Q53789447	Monoclonal Antibodies against the MET/HGF Receptor and Its Ligand: Multitask Tools with Applications from Basic Research to Therapy
Q34285473	Monovalency unleashes the full therapeutic potential of the DN-30 anti-Met antibody
Q27679191	Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent
Q37051227	Morphine-Induced Epidermal Growth Factor Pathway Activation in Non–Small Cell Lung Cancer
Q28594140	Mouse model of Noonan syndrome reveals cell type- and gene dosage-dependent effects of Ptpn11 mutation
Q35525305	Multiple mutations and bypass mechanisms can contribute to development of acquired resistance to MET inhibitors
Q27682271	Multisubstituted quinoxalines and pyrido[2,3-d]pyrimidines: Synthesis and SAR study as tyrosine kinase c-Met inhibitors
Q30537354	Mutant p53 enhances MET trafficking and signalling to drive cell scattering and invasion
Q40180061	Mutation and expression analyses of the MET and CDKN2A genes in rhabdomyosarcoma with emphasis on MET overexpression
Q40501703	N-WASP and WAVE2 acting downstream of phosphatidylinositol 3-kinase are required for myogenic cell migration induced by hepatocyte growth factor
Q40337339	N-cadherin-mediated cell motility requires cis dimers
Q39880907	NK4, an HGF antagonist, prevents hematogenous pulmonary metastasis by inhibiting adhesion of CT26 cells to endothelial cells
Q39399346	Nanobodies Targeting the Hepatocyte Growth Factor: Potential New Drugs for Molecular Cancer Therapy
Q30442626	Nanobody: the "magic bullet" for molecular imaging?
Q37363734	Necl2 regulates epidermal adhesion and wound repair
Q46835399	Neoadjuvant selective COX-2 inhibition down-regulates important oncogenic pathways in patients with esophageal adenocarcinoma
Q40228080	Neurofibromatosis-1 (Nf1) heterozygous brain microglia elaborate paracrine factors that promote Nf1-deficient astrocyte and glioma growth.
Q26998786	Neuropilins: expression and roles in the epithelium
Q37988056	New Insights into the Regulation of Epithelial–Mesenchymal Transition and Tissue Fibrosis
Q59136693	New drug developments in metastatic gastric cancer
Q36488744	New signals from the invasive front
Q86502674	Nobiletin attenuates metastasis via both ERK and PI3K/Akt pathways in HGF-treated liver cancer HepG2 cells
Q34236834	Non-agonistic bivalent antibodies that promote c-MET degradation and inhibit tumor growth and others specific for tumor related c-MET.
Q90169734	Noncoding Microdeletion in Mouse Hgf Disrupts Neural Crest Migration into the Stria Vascularis, Reduces the Endocochlear Potential, and Suggests the Neuropathology for Human Nonsyndromic Deafness DFNB39
Q30484106	Noncoding mutations of HGF are associated with nonsyndromic hearing loss, DFNB39.
Q49491161	Norleual, a hepatocyte growth factor and macrophage stimulating protein dual antagonist, increases pancreatic cancer sensitivity to gemcitabine
Q27015094	Normal morphogenesis of epithelial tissues and progression of epithelial tumors
Q92882785	Novel Peptide CM 7 Targeted c-Met with Antitumor Activity
Q35902144	Novel c-Met inhibitor suppresses the growth of c-Met-addicted gastric cancer cells
Q35221521	Novel roles of c-Met in the survival of renal cancer cells through the regulation of HO-1 and PD-L1 expression
Q30489228	Novel roles of hakai in cell proliferation and oncogenesis
Q38118439	Novel targets in HPV-negative head and neck cancer: overcoming resistance to EGFR inhibition
Q37263375	Novel targets with potential therapeutic applications in osteosarcoma
Q34249263	Novel therapies for metastatic castrate-resistant prostate cancer
Q28305555	Novel therapy for myocardial infarction: can HGF/Met be beneficial?
Q53013408	Nuclear Factor I-C acts as a regulator of hepatocyte proliferation at the onset of liver regeneration.
Q38812830	Nuclear phosphorylated Y142 β-catenin accumulates in astrocytomas and glioblastomas and regulates cell invasion
Q39824352	Numb regulates cell-cell adhesion and polarity in response to tyrosine kinase signalling
Q34420979	Obesity-mediated regulation of HGF/c-Met is associated with reduced basal-like breast cancer latency in parous mice
Q38817809	Oligonucleotide-Based Mimetics of Hepatocyte Growth Factor.
Q37966378	Oncogenic Pathways, Molecularly Targeted Therapies, and Highlighted Clinical Trials in Non–Small-Cell Lung Cancer (NSCLC)
Q39694500	Oncogenic engagement of the Met receptor is sufficient to evoke angiogenic, tumorigenic, and metastatic activities in rat intestinal epithelial cells
Q36355935	Osteopontin (OPN/SPP1) isoforms collectively enhance tumor cell invasion and dissemination in esophageal adenocarcinoma
Q54570544	Osthole Suppresses Hepatocyte Growth Factor (HGF)-Induced Epithelial-Mesenchymal Transition via Repression of the c-Met/Akt/mTOR Pathway in Human Breast Cancer Cells
Q39820864	Ovarian cancer cells stimulate uPA gene expression in fibroblastic stromal cells via multiple paracrine and autocrine mechanisms
Q90330482	Ovarian cancer: Current status and strategies for improving therapeutic outcomes
Q36092472	Ovarian cancer: emerging molecular-targeted therapies
Q36811730	Overexpression of MACC1 and Its significance in human Breast Cancer Progression.
Q35742089	Overexpression of MACC1 and the association with hepatocyte growth factor/c-Met in epithelial ovarian cancer
Q50936751	Overexpression of Metastasis-Associated in Colon Cancer-1 Associated with Poor Prognosis in Patients with Esophageal Cancer
Q36213128	Overexpression of PI3K p110α contributes to acquired resistance to MET inhibitor, in MET-amplified SNU-5 gastric xenografts
Q34141440	Overexpression of c-Met increases the tumor invasion of human prostate LNCaP cancer cells in vitro and in vivo
Q33868282	Overexpression of c-met in the early stage of pancreatic carcinogenesis; altered expression is not sufficient for progression from chronic pancreatitis to pancreatic cancer
Q36049932	Overexpression of metastasis-associated in colon cancer 1 predicts a poor outcome of hepatitis B virus-related hepatocellular carcinoma
Q34318050	Overexpression of sprouty 2 inhibits HGF/SF-mediated cell growth, invasion, migration, and cytokinesis.
Q35913323	Oxidation of heat shock protein 60 and protein disulfide isomerase activates ERK and migration of human hepatocellular carcinoma HepG2.
Q54514590	O‐Linked Triazolotriazines: Potent and Selective c‐Met Inhibitors
Q24646520	PAX3-FOXO1 fusion gene in rhabdomyosarcoma
Q38846778	PEA3 transcription factors are downstream effectors of Met signaling involved in migration and invasiveness of Met-addicted tumor cells.
Q35562996	PET of c-Met in Cancer with ⁶⁴Cu-Labeled Hepatocyte Growth Factor
Q30917936	PHA665752, a small-molecule inhibitor of c-Met, inhibits hepatocyte growth factor-stimulated migration and proliferation of c-Met-positive neuroblastoma cells
Q55256271	PI3K/AKT inhibition induces compensatory activation of the MET/STAT3 pathway in non-small cell lung cancer.
Q37679691	PKC and the control of localized signal dynamics.
Q54154496	PKCα promotes local advancement via its dual roles in nasopharyngeal carcinoma
Q36782617	PKCδ activated by c-MET enhances infiltration of human glioblastoma cells through NOTCH2 signaling
Q37376230	PKG II reverses HGF-triggered cellular activities by phosphorylating serine 985 of c-Met in gastric cancer cells
Q35188319	PTEN reconstitution alters glioma responses to c-Met pathway inhibition.
Q28238303	Pak4, a novel Gab1 binding partner, modulates cell migration and invasion by the Met receptor
Q92508947	Pancreatic Stellate Cells Facilitate Perineural Invasion of Pancreatic Cancer via HGF/c-Met Pathway
Q60043967	Pancreatic cancer associated with obesity and diabetes: an alternative approach for its targeting
Q39160643	Papillary Carcinoma of the Thyroid: High Expression of COX-2 and Low Expression of KAI-1/CD82 Are Associated with Increased Tumor Invasiveness
Q58585055	Parallel (Randomized) Phase II Evaluation of Tivantinib (ARQ197) and Tivantinib in Combination with Erlotinib in Papillary Renal Cell Carcinoma: SWOG S1107
Q26864275	Pathogenesis of RON receptor tyrosine kinase in cancer cells: activation mechanism, functional crosstalk, and signaling addiction
Q90422428	Pathway Mutations in Breast Cancer Using Whole-Exome Sequencing
Q33518855	Pericellular activation of hepatocyte growth factor by the transmembrane serine proteases matriptase and hepsin, but not by the membrane-associated protease uPA.
Q37723067	Pericyte depletion results in hypoxia-associated epithelial-to-mesenchymal transition and metastasis mediated by met signaling pathway
Q34271064	Perifosine as a potential novel anti-cancer agent inhibits EGFR/MET-AKT axis in malignant pleural mesothelioma
Q36729513	Peritoneal and hematogenous metastases of ovarian cancer cells are both controlled by the p90RSK through a self-reinforcing cell autonomous mechanism.
Q83820466	Peritumoral stromal remodeling, pattern of invasion and expression of c-met/HGF in advanced squamous cell carcinoma of the cervix uteri, FIGO stages III and IV
Q34273411	Phage displayed peptides/antibodies recognizing growth factors and their tyrosine kinase receptors as tools for anti-cancer therapeutics
Q28076200	Pharmacogenetics and pharmacogenomics as tools in cancer therapy
Q38442573	Pharmacokinetics and pharmacodynamics of rilotumumab: a decade of experience in preclinical and clinical cancer research
Q80371652	Pharmacokinetics and safety of a fully human hepatocyte growth factor antibody, AMG 102, in cynomolgus monkeys
Q37161161	Pharmacologic Inhibition of MEK Signaling Prevents Growth of Canine Hemangiosarcoma
Q38891575	Pharmacological Inhibition of KIT Activates MET Signaling in Gastrointestinal Stromal Tumors.
Q34964958	Phase 1 trial of tivantinib in combination with sorafenib in adult patients with advanced solid tumors
Q49962860	Phase 1b Trial of Ficlatuzumab, a Humanized Hepatocyte Growth Factor Inhibitory Monoclonal Antibody, in Combination With Gefitinib in Asian Patients With NSCLC.
Q37958152	Phase I and II Clinical Trials for Gastric Cancer
Q64296860	Phase I dose-escalation study of capmatinib (INC280) in Japanese patients with advanced solid tumors
Q33918113	Phase I ficlatuzumab monotherapy or with erlotinib for refractory advanced solid tumours and multiple myeloma
Q39137830	Phosphorylation of cMet tyrosine residues in murine ascitic hepatic cancer cell lines with different lymph node metastatic potentials
Q33905397	Phosphorylation-dependent differential regulation of plant growth, cell death, and innate immunity by the regulatory receptor-like kinase BAK1.
Q36852674	Plexin B1 suppresses c-Met in melanoma: a role for plexin B1 as a tumor-suppressor protein through regulation of c-Met
Q38022543	Plexin structures are coming: opportunities for multilevel investigations of semaphorin guidance receptors, their cell signaling mechanisms, and functions
Q30480866	Plexin-B1 mutations in prostate cancer
Q38853155	Polyphenols in Health and Disease
Q47842123	Population pharmacokinetic analysis from phase I and phase II studies of the humanized monovalent antibody, onartuzumab (MetMAb), in patients with advanced solid tumors.
Q38711090	Potential Antitumor Activity of SIM-89 in Non-Small Cell Lung Cancer Cells
Q47302253	Preclinical Evaluation of a Novel c-Met Inhibitor in a Gastric Cancer Xenograft Model Using Small Animal PET
Q39616531	Preclinical absorption, distribution, metabolism, excretion, and pharmacokinetic-pharmacodynamic modelling of N-(4-(3-((3S,4R)-1-ethyl-3-fluoropiperidine-4-ylamino)-1H-pyrazolo[3,4-b]pyridin-4-yloxy)-3-fluorophenyl)-2-(4-fluorophenyl)-3-oxo-2,3-dihy
Q37739479	Preclinical development of a humanized neutralizing antibody targeting HGF.
Q39373209	Preclinical evaluation of biomarkers for response monitoring to the MET inhibitor BAY-853474.
Q39436424	Preclinical stereoselective disposition and toxicokinetics of two novel MET inhibitors
Q43529428	Predictors of cervical lymph node metastasis in salivary gland cancer
Q53344481	Preeclampsia is associated with an elevation of plasma sMet concentrations in the second trimester
Q37101439	Prenatal Expression of MET Receptor Tyrosine Kinase in the Fetal Mouse Dorsal Raphe Nuclei and the Visceral Motor/Sensory Brainstem
Q58121324	Pretreatment plasma HGF as potential biomarker for susceptibility to radiation-induced liver dysfunction after radiotherapy
Q34161089	Primary resistance to cetuximab in a panel of patient-derived tumour xenograft models: Activation of MET as one mechanism for drug resistance
Q62030472	Pro-metastatic signaling by c-Met through RAC-1 and reactive oxygen species (ROS)
Q40418357	Proapoptotic function of the MET tyrosine kinase receptor through caspase cleavage
Q28071589	Profile of tivantinib and its potential in the treatment of hepatocellular carcinoma: the evidence to date
Q39893823	Profiling YB-1 target genes uncovers a new mechanism for MET receptor regulation in normal and malignant human mammary cells
Q54515534	Profiling immunohistochemical expression of NOTCH1-3, JAGGED1, cMET, and phospho-MAPK in 100 carcinomas of unknown primary.
Q36897569	Profiling phospho-signaling networks in breast cancer using reverse-phase protein arrays
Q34983997	Profiling the dynamics of a human phosphorylome reveals new components in HGF/c-Met signaling.
Q38287958	Progesterone regulates FGF10, MET, IGFBP1, and IGFBP3 in the endometrium of the ovine uterus.
Q43418210	Prognostic Value and Clinical Pathology of MACC-1 and c-MET Expression in Gastric Carcinoma
Q35836427	Prognostic and predictive significance of plasma HGF and IL-8 in a phase III trial of chemoradiation with or without tirapazamine in locoregionally advanced head and neck cancer
Q38493294	Prognostic and predictive value of MET deregulation in non-small cell lung cancer
Q37175089	Prognostic role of ERBB2, MET and VEGFA expression in metastatic colorectal cancer patients treated with anti-EGFR antibodies
Q55717696	Prognostic role of c-Met in head and neck squamous cell cancer tissues: a meta-analysis.
Q46170165	Prognostic significance of c-Met expression in glioblastomas
Q48397324	Prognostic significance of tetraspanin CD151 in newly diagnosed glioblastomas
Q38947146	Prognostic tissue biomarker exploration for patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor receptor tyrosine kinase inhibitors
Q33748638	Prognostic value of MET gene copy number and protein expression in patients with surgically resected non-small cell lung cancer: a meta-analysis of published literatures
Q35955290	Prognostic value of MET protein overexpression and gene amplification in locoregionally advanced nasopharyngeal carcinoma
Q36878125	Prognostic value of MET, cyclin D1 and MET gene copy number in non-small cell lung cancer
Q37322466	Programmed death ligand-1 expression and its prognostic role in esophageal squamous cell carcinoma.
Q34412775	Progranulin A-mediated MET signaling is essential for liver morphogenesis in zebrafish.
Q38007133	Progress in cancer therapy targeting c-Met signaling pathway
Q37739477	Progress of antibody-based inhibitors of the HGF-cMET axis in cancer therapy
Q26796405	Progress toward overcoming hypoxia-induced resistance to solid tumor therapy
Q33906737	Proliferation and invasion: plasticity in tumor cells
Q38502350	Promise and challenges on the horizon of MET-targeted cancer therapeutics
Q44500993	Promoter hypomethylation of the LINE-1 retrotransposable elements activates sense/antisense transcription and marks the progression of chronic myeloid leukemia
Q35212531	Propagating waves of directionality and coordination orchestrate collective cell migration.
Q28278555	Prostate cancer and the met hepatocyte growth factor receptor
Q37537958	Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches
Q28567709	Protein arginine methyltransferase 5 regulates ERK1/2 signal transduction amplitude and cell fate through CRAF
Q50915742	Protein expression status in mucosal and submucosal portions of early gastric cancers and their predictive value for lymph node metastasis
Q38952578	Protein tyrosine phosphatase PTPN3 inhibits lung cancer cell proliferation and migration by promoting EGFR endocytic degradation
Q54490877	Proteinase-activated receptor 2 (PAR2) in cholangiocarcinoma (CCA) cells: effects on signaling and cellular level
Q64077603	Proteolytic cleavages of MET: the divide-and-conquer strategy of a receptor tyrosine kinase
Q39166565	Proteome profiling of exosomes derived from human primary and metastatic colorectal cancer cells reveal differential expression of key metastatic factors and signal transduction components
Q37763945	Pseudo-active sites of protease domains: HGF/Met and Sonic hedgehog signaling in cancer
Q39980497	Quantitative PET imaging of Met-expressing human cancer xenografts with 89Zr-labelled monoclonal antibody DN30.
Q41860469	Quantitative Proteomics Identifies Activation of Hallmark Pathways of Cancer in Patient Melanoma
Q34655394	Quantitative analysis of EGFRvIII cellular signaling networks reveals a combinatorial therapeutic strategy for glioblastoma
Q33597170	Quantitative analysis of three-dimensional human mammary epithelial tissue architecture reveals a role for tenascin-C in regulating c-met function
Q37346559	Quantitative imaging for development of companion diagnostics to drugs targeting HGF/MET.
Q34327047	Quantitative imaging of epithelial cell scattering identifies specific inhibitors of cell motility and cell-cell dissociation.
Q35006543	Quantitative proteomics discloses MET expression in mitochondria as a direct target of MET kinase inhibitor in cancer cells.
Q38875292	Quercetin inhibits HGF/c-Met signaling and HGF-stimulated melanoma cell migration and invasion.
Q38803278	Quinoxaline-Based Scaffolds Targeting Tyrosine Kinases and Their Potential Anticancer Activity
Q37648868	RANK- and c-Met-mediated signal network promotes prostate cancer metastatic colonization
Q40456936	RNAi technology and lentiviral delivery as a powerful tool to suppress Tpr-Met-mediated tumorigenesis.
Q33721142	RON and c-Met facilitate metastasis through the ERK signaling pathway in prostate cancer cells
Q44392303	Radiosensitization of brain metastasis by targeting c-MET
Q34293078	Radiosensitization of glioma cells by modulation of Met signalling with the hepatocyte growth factor neutralizing antibody, AMG102
Q39619874	RalA function in dermal fibroblasts is required for the progression of squamous cell carcinoma of the skin.
Q52678686	Randomized phase 2 study of tivantinib plus erlotinib versus single-agent chemotherapy in previously treated KRAS mutant advanced non-small cell lung cancer.
Q35010777	Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer
Q35212113	Randomized phase Ib/II trial of rilotumumab or ganitumab with panitumumab versus panitumumab alone in patients with wild-type KRAS metastatic colorectal cancer
Q35221992	Rapid growth of invasive metastatic melanoma in carcinogen-treated hepatocyte growth factor/scatter factor-transgenic mice carrying an oncogenic CDK4 mutation
Q36621024	Rapid modification of the bone microenvironment following short-term treatment with Cabozantinib in vivo.
Q40052806	Ras isoform abundance and signalling in human cancer cell lines.
Q54628931	Reaction of plasma hepatocyte growth factor levels in non-small cell lung cancer patients treated with EGFR-TKIs.
Q26778234	Recent Developments in Active Tumor Targeted Multifunctional Nanoparticles for Combination Chemotherapy in Cancer Treatment and Imaging
Q50985091	Recent Progress and Advances in HGF/MET-Targeted Therapeutic Agents for Cancer Treatment
Q38982398	Receptor ligand-triggered resistance to alectinib and its circumvention by Hsp90 inhibition in EML4-ALK lung cancer cells.
Q36860354	Receptor trafficking controls weak signal delivery: a strategy used by c-Met for STAT3 nuclear accumulation.
Q42459082	Receptor tyrosine kinase c-Met controls the cytoskeleton from different endosomes via different pathways.
Q43425542	Receptor tyrosine kinases MET and RON as prognostic factors in diffuse large B‐cell lymphoma patients receiving R‐CHOP
Q28082793	Receptor tyrosine kinases: Characterisation, mechanism of action and therapeutic interests for bone cancers
Q35102025	Receptor-Tyrosine-Kinase-Targeted Therapies for Head and Neck Cancer
Q87768178	Receptor-ligand interactions: binding affinities studied by single-molecule and super-resolution microscopy on intact cells
Q34963286	Receptor-type Protein Tyrosine Phosphatase β (RPTP-β) Directly Dephosphorylates and Regulates Hepatocyte Growth Factor Receptor (HGFR/Met) Function
Q38736579	Recombinant IL-7/HGFβ hybrid cytokine separates acute graft-versus-host-disease from graft-versus-tumour activity by altering donor T cell trafficking
Q38735138	Recurrent MET fusion genes represent a drug target in pediatric glioblastoma
Q40443617	Redundant roles for Met docking site tyrosines and the Gab1 pleckstrin homology domain in InlB-mediated entry of Listeria monocytogenes
Q41529413	Regulation of HGF-induced hepatocyte proliferation by the small GTPase Arf6 through the PIP2-producing enzyme PIP5K1A
Q36738312	Regulation of MAPKs by growth factors and receptor tyrosine kinases
Q36886944	Regulation of MET by FOXP2, genes implicated in higher cognitive dysfunction and autism risk
Q28290742	Regulation of c-Met-dependent gene expression by PTEN
Q46938705	Regulation of c-met expression by transcription repressor Daxx
Q41814094	Regulation of cell migration via the EGFR signaling pathway in oral squamous cell carcinoma cells
Q35084939	Regulation of hepatocyte activator inhibitor-1 expression by androgen and oncogenic transformation in the prostate
Q24316395	Regulation of the Met receptor-tyrosine kinase by the protein-tyrosine phosphatase 1B and T-cell phosphatase
Q34202118	Removing intensity effects and identifying significant genes for Affymetrix arrays in macrophage migration inhibitory factor-suppressed neuroblastoma cells.
Q97519820	Research Progress on Slit/Robo Pathway in Pancreatic Cancer: Emerging and Promising
Q90347558	Resistance Mechanisms to Anti-angiogenic Therapies in Cancer
Q37487158	Resistance mechanisms of tumour cells to EGFR inhibitors
Q52579594	Resistance to Anti-Angiogenic Therapy in Cancer-Alterations to Anti-VEGF Pathway.
Q37463413	Revisiting the seed and soil in cancer metastasis
Q46920527	Rho/ROCK-dependent pseudopodial protrusion and cellular blebbing are regulated by p38 MAPK in tumour cells exhibiting autocrine c-Met activation
Q50541927	Role of AMP-activated protein kinase in the control of hepatocyte priming and proliferation during liver regeneration
Q35200337	Role of HGF/MET axis in resistance of lung cancer to contemporary management
Q33786333	Role of LPAR3, PKC and EGFR in LPA-induced cell migration in oral squamous carcinoma cells
Q91306867	Role of c-Met expression on prognosis of head and neck cancer: A literature review and meta-analysis
Q39839983	Role of c-Met in cancer: emphasis on lung cancer
Q38134309	Role of cMET in the development and progression of colorectal cancer
Q36680692	Role of carbonic anhydrases in the progression of renal cell carcinoma subtypes: proposal of a unified hypothesis
Q37065772	Role of cyclin D1 as a mediator of c-Met- and beta-catenin-induced hepatocarcinogenesis
Q39448192	Role of insulin-like growth factor-II mRNA-binding protein-3 in invadopodia formation and the growth of oral squamous cell carcinoma in athymic nude mice
Q38167258	Role of met axis in head and neck cancer
Q37565675	Role of overexpression of MACC1 and/or FAK in predicting prognosis of hepatocellular carcinoma after liver transplantation
Q49887930	Role of the HGF/c-MET tyrosine kinase inhibitors in metastasic melanoma.
Q43559869	SB365, Pulsatilla saponin D, targets c-Met and exerts antiangiogenic and antitumor activities
Q55054888	SGK1 inhibition-induced autophagy impairs prostate cancer metastasis by reversing EMT.
Q36346565	SNPs in the coding region of the metastasis-inducing gene MACC1 and clinical outcome in colorectal cancer
Q52841133	SOCS1 inhibits migration and invasion of prostate cancer cells, attenuates tumor growth and modulates the tumor stroma.
Q50422607	SPRY2 is a novel MET interactor that regulates metastatic potential and differentiation in rhabdomyosarcoma.
Q47074089	STAT3-dependent pathfinding and control of axonal branching and target selection
Q36133180	Safety of Onartuzumab in Patients with Solid Tumors: Experience to Date from the Onartuzumab Clinical Trial Program
Q24683896	Scatter factor/hepatocyte growth factor in brain tumor growth and angiogenesis
Q34318015	Searching for the hereditary causes of renal-cell carcinoma
Q54970742	Second-line treatments: moving towards an opportunity to improve survival in advanced gastric cancer?
Q37389699	Selecting Tumor-Specific Molecular Targets in Pancreatic Adenocarcinoma: Paving the Way for Image-Guided Pancreatic Surgery
Q37730020	Selection criteria for c-Met-targeted therapies: emerging evidence for biomarkers
Q51970500	Semaphorin-3A guides radial migration of cortical neurons during development.
Q33833881	Senescent cells as a source of inflammatory factors for tumor progression
Q39385631	Sensitivity of Selected Human Tumor Models to PF-04217903, a Novel Selective c-Met Kinase Inhibitor
Q37275172	Serine protease HtrA1 associates with microtubules and inhibits cell migration
Q33682988	Serum levels of hepatocyte growth factor and epiregulin are associated with the prognosis on anti-EGFR antibody treatment in KRAS wild-type metastatic colorectal cancer
Q39336251	Shedding-generated Met receptor fragments can be routed to either the proteasomal or the lysosomal degradation pathway
Q48171680	Shikonin Inhibited Migration and Invasion of Human Lung Cancer Cells via Suppression of c-Met-Mediated Epithelial-to-Mesenchymal Transition.
Q45318112	Signaling by MET
Q92636095	Significance of 5-S-Cysteinyldopa as a Marker for Melanoma
Q42735478	Silencing Met receptor tyrosine kinase signaling decreased oral tumor growth and increased survival of nude mice.
Q89545812	Silencing of MUC20 suppresses the malignant character of pancreatic ductal adenocarcinoma cells through inhibition of the HGF/MET pathway
Q58164852	Silencing the MET oncogene leads to regression of experimental tumors and metastases
Q37437415	Simm530, a novel and highly selective c-Met inhibitor, blocks c-Met-stimulated signaling and neoplastic activities
Q55069452	Simultaneous Monitoring of Cell-surface Receptor and Tumor-targeted Photodynamic Therapy via TdT-initiated Poly-G-Quadruplexes.
Q33816457	Single chain anti-c-Met antibody conjugated nanoparticles for in vivo tumor-targeted imaging and drug delivery
Q34753763	Single-molecule photobleaching reveals increased MET receptor dimerization upon ligand binding in intact cells
Q38993797	Slit2 promotes tumor growth and invasion in chemically induced skin carcinogenesis
Q35757384	Slug is required for cell survival during partial epithelial-mesenchymal transition of HGF-induced tubulogenesis
Q34094632	Small molecule c-Met kinase inhibitors: a review of recent patents
Q34992505	Small molecule substrate phosphorylation site inhibitors of protein kinases: approaches and challenges.
Q39369722	Small molecule tolfenamic acid inhibits PC-3 cell proliferation and invasion in vitro, and tumor growth in orthotopic mouse model for prostate cancer.
Q38333967	Small proline-rich proteins 2 are noncoordinately upregulated by IL-6/STAT3 signaling after bile duct ligation
Q37638679	Small-molecule inhibitors of the human epidermal receptor family.
Q34158454	Small-molecule inhibitors of the receptor tyrosine kinases: promising tools for targeted cancer therapies
Q46971338	Solid predominant histology predicts EGFR tyrosine kinase inhibitor response in patients with EGFR mutation-positive lung adenocarcinoma
Q44643220	Soluble c-Met in serum of patients with multiple myeloma: correlation with clinical parameters
Q37111358	Somatic mutation and functional polymorphism of a novel regulatory element in the HGF gene promoter causes its aberrant expression in human breast cancer
Q35828564	Sorafenib and DE605, a novel c-Met inhibitor, synergistically suppress hepatocellular carcinoma
Q38635603	Sorafenib-based combined molecule targeting in treatment of hepatocellular carcinoma
Q89151963	Spatial regulation of signaling by the coordinated action of the protein tyrosine kinases MET and FER
Q40318601	Species specificity of the Listeria monocytogenes InlB protein.
Q38302515	Specific Grb2-mediated interactions regulate clathrin-dependent endocytosis of the cMet-tyrosine kinase
Q37098168	Specific fate decisions in adult hepatic progenitor cells driven by MET and EGFR signaling
Q36734746	Specific inhibitors of the protein tyrosine phosphatase Shp2 identified by high-throughput docking.
Q36846833	Starvation after Cobalt-60 γ-Ray Radiation Enhances Metastasis in U251 Glioma Cells by Regulating the Transcription Factor SP1.
Q45749691	Stem cell CD44v isoforms promote intestinal cancer formation in Apc(min) mice downstream of Wnt signaling
Q55317592	Stepwise participation of HGF/MET signaling in the development of migratory muscle precursors during vertebrate evolution.
Q39145880	Strengthening Context-Dependent Anticancer Effects on Non–Small Cell Lung Carcinoma by Inhibition of Both MET and EGFR
Q29618873	Stromal fibroblasts in cancer initiation and progression
Q39641555	Strong neurogenesis, angiogenesis, synaptogenesis, and antifibrosis of hepatocyte growth factor in rats brain after transient middle cerebral artery occlusion
Q27666642	Structural Basis for Selective Small Molecule Kinase Inhibition of Activated c-Met
Q38431115	Structural Basis of TPR-Mediated Oligomerization and Activation of Oncogenic Fusion Kinases.
Q40541604	Structural and functional basis of the serine protease-like hepatocyte growth factor beta-chain in Met binding and signaling
Q27663368	Structural basis for agonism and antagonism of hepatocyte growth factor
Q36185383	Structural basis for specific self-incompatibility response in Brassica.
Q38057539	Structural basis of MET receptor dimerization by the bacterial invasion protein InlB and the HGF/SF splice variant NK1
Q34572895	Structural basis of hepatocyte growth factor/scatter factor and MET signalling
Q24307789	Structural characterization of autoinhibited c-Met kinase produced by coexpression in bacteria with phosphatase
Q47155329	Structural determinant of BST-2-mediated regulation of breast cancer cell motility: a role for cytoplasmic tail tyrosine residues
Q36559850	Structure and function of glycosphingolipids and sphingolipids: recollections and future trends
Q24323145	Structure of the human receptor tyrosine kinase met in complex with the Listeria invasion protein InlB
Q44283525	Study of MET protein levels and MET gene copy number in 72 sinonasal intestinal-type adenocarcinomas
Q39147437	Sulphonamido-quinoxalines: Search for anticancer agent
Q42425978	Survival of the weakest: signaling aided by endosomes
Q34062598	Synergistic role of sprouty2 inactivation and c-Met up-regulation in mouse and human hepatocarcinogenesis
Q39127629	Synthesis and biological evaluation of 4-phenoxy-6,7-disubstituted quinolines possessing semicarbazone scaffolds as selective c-Met inhibitors.
Q39575995	Synthesis and c-Met Kinase Inhibition of 3,5-Disubstituted and 3,5,7-Trisubstituted Quinolines: Identification of 3-(4-Acetylpiperazin-1-yl)-5-(3-nitrobenzylamino)-7- (trifluoromethyl)quinoline as a Novel Anticancer Agent
Q59129187	Synthesis of novel 6,7-dimethoxy-4-anilinoquinolines as potent c-Met inhibitors
Q35129076	Synthetic lethal screening reveals FGFR as one of the combinatorial targets to overcome resistance to Met-targeted therapy
Q35525917	TAK-701, a humanized monoclonal antibody to hepatocyte growth factor, reverses gefitinib resistance induced by tumor-derived HGF in non-small cell lung cancer with an EGFR mutation
Q34794927	TAM receptor tyrosine kinases: biologic functions, signaling, and potential therapeutic targeting in human cancer
Q64108520	TGFβ-induced cytoskeletal remodeling mediates elevation of cell stiffness and invasiveness in NSCLC
Q90029670	TGFβ1 regulates HGF-induced cell migration and hepatocyte growth factor receptor MET expression via C-ets-1 and miR-128-3p in basal-like breast cancer
Q34754045	Tailoring tyrosine kinase inhibitors to fit the lung cancer genome.
Q37862154	Tangled fibroblasts in tumor‐stroma interactions
Q42582783	Target therapy in NSCLC patients: Relevant clinical agents and tumour molecular characterisation
Q38100162	Targeted agents in non-small cell lung cancer therapy: What is there on the horizon?
Q36643088	Targeted inhibition of heat shock protein 90 disrupts multiple oncogenic signaling pathways, thus inducing cell cycle arrest and programmed cell death in human urinary bladder cancer cell lines
Q35628597	Targeted therapies for non-small cell lung cancer: an evolving landscape
Q27022852	Targeted therapies in development for non-small cell lung cancer
Q48019064	Targeting H19 by lentivirus-mediated RNA interference increases A549 cell migration and invasion
Q34309927	Targeting MET Amplification as a New Oncogenic Driver.
Q38835745	Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma
Q39484796	Targeting MET by tyrosine kinase inhibitor suppresses growth and invasion of nasopharyngeal carcinoma cell lines
Q37978193	Targeting MET in cancer: rationale and progress
Q38723404	Targeting Met and VEGFR Axis in Metastatic Castration-Resistant Prostate Cancer: 'Game Over'?
Q38110043	Targeting Molecular Aberrations in Urothelial Carcinoma: Are We Almost There?
Q47102665	Targeting RhoC by Way of Ribozyme Trangene in Human Breast Cancer Cells and its Impact on Cancer Invasion
Q37978315	Targeting Strategies for Multifunctional Nanoparticles in Cancer Imaging and Therapy
Q64253749	Targeting Tyrosine kinases in Renal Cell Carcinoma: "New Bullets against Old Guys"
Q42683185	Targeting WNT Signaling for Multifaceted Glioblastoma Therapy
Q26863249	Targeting bone physiology for the treatment of metastatic prostate cancer
Q55032209	Targeting c-MET by LY2801653 for treatment of cholangiocarcinoma.
Q64113657	Targeting c-MET by Tivantinib through synergistic activation of JNK/c-jun pathway in cholangiocarcinoma
Q37964341	Targeting c-Met as a promising strategy for the treatment of hepatocellular carcinoma
Q35153149	Targeting c-Met receptor overcomes TRAIL-resistance in brain tumors
Q37068767	Targeting genomic alterations in squamous cell lung cancer
Q35985323	Targeting of DNA molecules, BSA/c-Met tyrosine kinase receptors and anti-proliferative activity of bis(terpyridine)copper(ii) complexes
Q27022941	Targeting oncogenic ALK and MET: a promising therapeutic strategy for glioblastoma
Q38234910	Targeting pleiotropic signaling pathways to control adult cardiac stem cell fate and function.
Q36766188	Targeting the HGF-cMET Axis in Hepatocellular Carcinoma
Q37013777	Targeting the HGF/Met signaling pathway in cancer therapy
Q36142604	Targeting the HGF/Met signalling pathway in cancer.
Q61814439	Targeting the Hepatocyte Growth Factor and c-Met Signaling Axis in Bone Metastases
Q38297235	Targeting the MET pathway for potential treatment of NSCLC.
Q38261315	Targeting the MET receptor tyrosine kinase in non-small cell lung cancer: emerging role of tivantinib
Q38002473	Targeting the Met pathway in lung cancer
Q37331862	Targeting the Met signaling pathway in renal cancer.
Q50026654	Targeting the cMET pathway augments radiation response without adverse effect on hearing in NF2 schwannoma models
Q42171605	Targeting the hsp70 gene delays mammary tumor initiation and inhibits tumor cell metastasis
Q38097602	Targeting tumor cell motility as a strategy against invasion and metastasis
Q33984904	Tensin-4-dependent MET stabilization is essential for survival and proliferation in carcinoma cells
Q40343230	Tetraspanin KAI1/CD82 suppresses invasion by inhibiting integrin-dependent crosstalk with c-Met receptor and Src kinases
Q37739091	Tetraspanins Function as Regulators of Cellular Signaling.
Q98237511	The AKT-independent MET-V-ATPase-MTOR axis suppresses liver cancer vaccination
Q47411655	The Advantages of Targeted Protein Degradation Over Inhibition: An RTK Case Study
Q42143312	The Antitumor Effect of C-terminus of Hsp70-Interacting Protein via Degradation of c-Met in Small Cell Lung Cancer
Q42230629	The EGFR-GEP100-Arf6 pathway in breast cancer: Full invasiveness is not from the inside
Q37292195	The EGFR-GEP100-Arf6-AMAP1 signaling pathway specific to breast cancer invasion and metastasis
Q89967621	The Function of the HGF/c-Met Axis in Hepatocellular Carcinoma
Q35740444	The HGF inhibitory peptide HGP-1 displays promising in vitro and in vivo efficacy for targeted cancer therapy
Q91754947	The HGF-MET axis coordinates liver cancer metabolism and autophagy for chemotherapeutic resistance
Q46358843	The HGF/c-MET Pathway Is a Driver and Biomarker of VEGFR-inhibitor Resistance and Vascular Remodeling in Non-Small Cell Lung Cancer
Q42811812	The HSP90 inhibitor ganetespib synergizes with the MET kinase inhibitor crizotinib in both crizotinib-sensitive and -resistant MET-driven tumor models
Q34141913	The Hepatocyte Growth Factor Receptor: Structure, Function and Pharmacological Targeting in Cancer
Q54117888	The Impact of the Epithelial-Mesenchymal Transition Regulator Hepatocyte Growth Factor Receptor/Met on Skin Immunity by Modulating Langerhans Cell Migration
Q37933095	The Inflammatory Tumor Microenvironment, Epithelial Mesenchymal Transition and Lung Carcinogenesis
Q38346325	The Intricate Interplay between Mechanisms Underlying Aging and Cancer
Q40424985	The Listeria protein internalin B mimics hepatocyte growth factor-induced receptor trafficking
Q35488562	The MET gene is a common integration target in avian leukosis virus subgroup J-induced chicken hemangiomas
Q39389679	The MET oncogene transforms human primary bone-derived cells into osteosarcomas by targeting committed osteo-progenitors
Q40213344	The MET receptor tyrosine kinase contributes to invasive tumour growth in rhabdomyosarcomas
Q36868644	The MET receptor tyrosine kinase in invasion and metastasis
Q40500532	The Met protooncogene is a transcriptional target of NF kappaB: implications for cell survival
Q42142440	The Met receptor tyrosine kinase prevents zebrafish primary motoneurons from expressing an incorrect neurotransmitter
Q35078950	The Molecular Crosstalk between the MET Receptor Tyrosine Kinase and the DNA Damage Response-Biological and Clinical Aspects
Q33769333	The ORF3 protein of hepatitis E virus delays degradation of activated growth factor receptors by interacting with CIN85 and blocking formation of the Cbl-CIN85 complex
Q39000582	The Pim-1 protein kinase is an important regulator of MET receptor tyrosine kinase levels and signaling
Q39698521	The Protein Tyrosine Kinase Inhibitor Tyrphostin 23 Strongly Accelerates Glycolytic Lactate Production in Cultured Primary Astrocytes.
Q34919909	The Role of Placental Homeobox Genes in Human Fetal Growth Restriction
Q24314397	The Slit/Robo system suppresses hepatocyte growth factor-dependent invasion and morphogenesis
Q38674137	The Therapeutic Targeting of HGF/c-Met Signaling in Hepatocellular Carcinoma: Alternative Approaches
Q40317015	The Wnt pathway destabilizes adherens junctions and promotes cell migration via β‐catenin and its target gene cyclin D1
Q36792806	The Zinc Transporter Zip14 Influences c-Met Phosphorylation and Hepatocyte Proliferation During Liver Regeneration in Mice
Q55065289	The absolute bioavailability investigation of LS177 in rats using ultra-performance liquid chromatography-tandem mass spectrometry.
Q36815851	The autism risk genes MET and PLAUR differentially impact cortical development
Q42679093	The autism susceptibility gene met regulates zebrafish cerebellar development and facial motor neuron migration
Q37617598	The bacterial peptidoglycan-sensing molecule Pglyrp2 modulates brain development and behavior
Q38357819	The binding properties of minimal oligosaccharides reveal a common heparan sulfate/dermatan sulfate-binding site in hepatocyte growth factor/scatter factor that can accommodate a wide variety of sulfation patterns
Q28066460	The biological complexity of colorectal cancer: insights into biomarkers for early detection and personalized care
Q39760115	The c-Met receptor tyrosine kinase inhibitor MP470 radiosensitizes glioblastoma cells
Q39274990	The c-Met receptor: Implication for targeted therapies in colorectal cancer
Q30157772	The carboxyl-terminal SH3 domain of the mammalian adaptor CrkII promotes internalization of Listeria monocytogenes through activation of host phosphoinositide 3-kinase
Q28081415	The clinical and functional significance of c-Met in breast cancer: a review
Q36127679	The clinicopathologic association of c-MET overexpression in Iranian gastric carcinomas; an immunohistochemical study of tissue microarrays
Q38173257	The complex function of hsp70 in metastatic cancer.
Q36720868	The concurrent chemoradiation paradigm--general principles
Q34365135	The current status of tailor-made medicine with molecular biomarkers for patients with clear cell renal cell carcinoma
Q42038856	The cytohesin guanosine exchange factors (GEFs) are required to promote HGF-mediated renal recovery after acute kidney injury (AKI) in mice.
Q30534479	The decreased metastatic potential of rhabdomyosarcoma cells obtained through MET receptor downregulation and the induction of differentiation
Q38085900	The emerging role of MET/HGF inhibitors in oncology
Q34852043	The evolving genomic classification of lung cancer
Q82941868	The expression of hepatocyte growth factor (HGF) and c-Met in uterine serous carcinoma
Q38845494	The formation of epithelial tubes
Q37621003	The function, proteolytic processing, and histopathology of Met in cancer
Q40322516	The green tea catechins, (-)-Epigallocatechin-3-gallate (EGCG) and (-)-Epicatechin-3-gallate (ECG), inhibit HGF/Met signaling in immortalized and tumorigenic breast epithelial cells
Q38078480	The heparanase/syndecan‐1 axis in cancer: mechanisms and therapies
Q35904618	The hepatocyte growth factor receptor as a potential therapeutic target for dedifferentiated liposarcoma
Q35563524	The hepatocyte growth factor/c-Met signaling pathway as a therapeutic target to inhibit angiogenesis
Q38063931	The methylation landscape of tumour metastasis
Q33275745	The molecular aspects of chordoma
Q35111736	The molecular pathogenesis of head and neck cancer
Q36273639	The motility-proliferation-metabolism interplay during metastatic invasion
Q52316580	The multiple paths towards MET receptor addiction in cancer.
Q36907124	The novel c-Met inhibitor cabozantinib overcomes gemcitabine resistance and stem cell signaling in pancreatic cancer
Q39594896	The orally bioavailable met inhibitor PF-2341066 inhibits osteosarcoma growth and osteolysis/matrix production in a xenograft model
Q28066094	The potential therapeutic applications and prognostic significance of metastasis-associated in colon cancer-1 (MACC1) in cancers
Q53562884	The prognostic impact of EGFR, ErbB2 and MET gene amplification in human gastric carcinomas as measured by quantitative Real-Time PCR.
Q38021684	The rejuvenated scenario of epithelial-mesenchymal transition (EMT) and cancer metastasis
Q37950469	The role of HGF/c-Met signaling in prostate cancer progression and c-Met inhibitors in clinical trials
Q38211082	The role of inflammation in sarcoma
Q37854698	The secret second life of an innocent chaperone: the story of CD74 and B cell/chronic lymphocytic leukemia cell survival
Q38704952	The selective c-Met inhibitor tepotinib can overcome epidermal growth factor receptor inhibitor resistance mediated by aberrant c-Met activation in NSCLC models
Q29620106	The senescence-associated secretory phenotype: the dark side of tumor suppression
Q42175777	The septum transversum mesenchyme induces gall bladder development
Q36961606	The shadow of death on the MET tyrosine kinase receptor
Q30587438	The three-way switch operation of Rac1/RhoA GTPase-based circuit controlling amoeboid-hybrid-mesenchymal transition
Q24613885	The transcription factor LSF: a novel oncogene for hepatocellular carcinoma
Q53222639	The transcription factor PAX2 regulates ADAM10 expression in renal cell carcinoma.
Q28077074	The tumor microenvironment in esophageal cancer
Q37179521	The tumor microenvironment: An irreplaceable element of tumor budding and epithelial-mesenchymal transition-mediated cancer metastasis
Q36627750	The tumor microenvironment: key to early detection
Q39114252	The tumour suppressor miR-34c targets MET in prostate cancer cells
Q36407783	The tyrosine kinase c-Met contributes to the pro-tumorigenic function of the p38 kinase in human bile duct cholangiocarcinoma cells
Q35080738	The von Hippel-Lindau tumor suppressor gene product represses oncogenic beta-catenin signaling in renal carcinoma cells
Q36840731	Therapeutic Strategies for Bone Metastases and Their Clinical Sequelae in Prostate Cancer
Q132730811	Therapeutic implications of signaling pathways and tumor microenvironment interactions in esophageal cancer
Q33696791	Therapeutic potential of TAS-115 via c-MET and PDGFRα signal inhibition for synovial sarcoma
Q36915616	Therapeutic targeting of human hepatocyte growth factor with a single neutralizing monoclonal antibody reduces lung tumorigenesis
Q40926975	Thiocarbamate-linked polysulfonate-peptide conjugates as selective hepatocyte growth factor receptor binders.
Q39773426	Tissue factor mediates the HGF/Met-induced anti-apoptotic pathway in DAOY medulloblastoma cells.
Q55058147	Tissue miRNA 483-3p expression predicts tumor recurrence after surgical resection in histologically advanced hepatocellular carcinomas.
Q33401272	Tivantinib (ARQ 197), a selective inhibitor of MET, in patients with microphthalmia transcription factor-associated tumors: results of a multicenter phase 2 trial
Q39246053	Tivantinib for the treatment of hepatocellular carcinoma
Q36156854	Tivantinib induces G2/M arrest and apoptosis by disrupting tubulin polymerization in hepatocellular carcinoma
Q38259343	Tivantinib: critical review with a focus on hepatocellular carcinoma.
Q37118314	Topographic gene expression in the sinonasal cavity of patients with chronic sinusitis with polyps
Q34478843	Toward Libraries of Biotinylated Chondroitin Sulfate Analogues: From Synthesis to In Vivo Studies
Q34296542	Toward quantitative phosphotyrosine profiling in vivo.
Q41626594	Tpl2 regulates intestinal myofibroblast HGF release to suppress colitis-associated tumorigenesis.
Q92695080	Traction microscopy with integrated microfluidics: responses of the multi-cellular island to gradients of HGF
Q30436756	Transcription-dependent epidermal growth factor receptor activation by hepatocyte growth factor
Q39607677	Transcriptional Profiling Identifies TNS4 Function in Epithelial Tubulogenesis
Q45939821	Transfection of HGF gene enhances endothelial progenitor cell (EPC) function and improves EPC transplant efficiency for balloon-induced arterial injury in hypercholesterolemic rats.
Q43840478	Treatment Rationale and Study Design for a Randomized, Double-Blind, Placebo-Controlled Phase II Study Evaluating Onartuzumab (MetMAb) in Combination With Bevacizumab Plus mFOLFOX-6 in Patients With Previously Untreated Metastatic Colorectal Cancer
Q42645319	Trekking through the telencephalon: hepatocyte growth factor-mediated guidance for parvalbumin-expressing interneurons.
Q38777675	Trends in the development of MET inhibitors for hepatocellular carcinoma
Q41660598	Tumor Inhibitory Effect of IRCR201, a Novel Cross-Reactive c-Met Antibody Targeting the PSI Domain.
Q36439444	Tumor MET expression profile predicts the outcome of non-small cell lung cancer patients receiving epidermal growth factor receptor tyrosine kinase inhibitors.
Q80332141	Tumor hypoxia and expression of c-met in cervical cancer
Q27308951	Tumor invasion optimization by mesenchymal-amoeboid heterogeneity
Q29617676	Tumor metastasis: mechanistic insights and clinical challenges
Q36249219	Tumor-derived hepatocyte growth factor is associated with poor prognosis of patients with glioma and influences the chemosensitivity of glioma cell line to cisplatin in vitro
Q33643964	Tumor-stroma interactions
Q38882535	Tumor-suppressive p53 Signaling Empowers Metastatic Inhibitor KLF17-dependent Transcription to Overcome Tumorigenesis in Non-small Cell Lung Cancer
Q42098072	Tyrosine dephosphorylated cortactin downregulates contractility at the epithelial zonula adherens through SRGAP1.
Q38262816	Tyrosine kinase inhibitors in the treatment of prostate cancer: taking the next step in clinical development
Q28577530	Tyrosine residues 654 and 670 in beta-catenin are crucial in regulation of Met-beta-catenin interactions
Q37476722	USP8 is a novel target for overcoming gefitinib resistance in lung cancer
Q38994990	USP8 modulates ubiquitination of LRIG1 for Met degradation
Q26748581	Understanding and Targeting MET Signaling in Solid Tumors - Are We There Yet?
Q38083967	Understanding the functions of tumor stroma in resistance to ionizing radiation: Emerging targets for pharmacological modulation
Q37948053	Understanding tumor-stroma interplays for targeted therapies by armed mesenchymal stromal progenitors: the Mesenkillers
Q37721218	Update on the Treatment of Metastatic Squamous Non-Small Cell Lung Cancer in New Era of Personalized Medicine
Q54375509	Upregulation of HGF and c-MET is associated with subclinical central lymph node metastasis in papillary thyroid microcarcinoma.
Q35689753	Utilizing the activation mechanism of serine proteases to engineer hepatocyte growth factor into a Met antagonist
Q35112894	VEGF and c-Met Blockade Amplify Angiogenesis Inhibition in Pancreatic Islet Cancer
Q24293027	VEGF inhibits tumor cell invasion and mesenchymal transition through a MET/VEGFR2 complex
Q90211933	VHH-Photosensitizer Conjugates for Targeted Photodynamic Therapy of Met-Overexpressing Tumor Cells
Q37199026	VHL loss of function and its impact on oncogenic signaling networks in clear cell renal cell carcinoma
Q33850376	Valproic acid, targets papillary thyroid cancer through inhibition of c-Met signalling pathway
Q36563092	Value of c-Met for predicting progression of precancerous gastric lesions in rural Chinese population
Q92798815	Verticillin A suppresses HGF-induced migration and invasion via repression of the c-Met/FAK/Src pathway in human gastric and cervical cancer cells
Q38953922	Volitinib, a potent and highly selective c-Met inhibitor, effectively blocks c-Met signaling and growth in c-MET amplified gastric cancer patient-derived tumor xenograft models
Q37472110	c-MET as a Potential Therapeutic Target in Ovarian Clear Cell Carcinoma
Q38165247	c-MET kinase inhibitors: a patent review (2011 - 2013).
Q58796893	c-MET receptor as potential biomarker and target molecule for malignant testicular germ cell tumors
Q38923535	c-MET receptor tyrosine kinase as a molecular target in advanced hepatocellular carcinoma
Q27300880	c-MET regulates myoblast motility and myocyte fusion during adult skeletal muscle regeneration
Q39405746	c-MET: an exciting new target for anticancer therapy
Q34342411	c-Met Modulates RPE Migratory Response to Laser-Induced Retinal Injury
Q36441220	c-Met Overexpression in Cervical Cancer, a Prognostic Factor and a Potential Molecular Therapeutic Target.
Q35242044	c-Met activation through a novel pathway involving osteopontin mediates oncogenesis by the transcription factor LSF
Q50985108	c-Met and Other Cell Surface Molecules: Interaction, Activation and Functional Consequences
Q40472507	c-Met and its ligand hepatocyte growth factor/scatter factor regulate mature B cell survival in a pathway induced by CD74.
Q51158233	c-Met and miRs in Cancer
Q91997148	c-Met as a new marker of cellular senescence
Q37651008	c-Met expression and activity in urogenital cancers - novel aspects of signal transduction and medical implications
Q54650716	c-Met expression is associated with time to recurrence in patients with glioblastoma multiforme
Q38316196	c-Met expression is regulated by Mitf in the melanocyte lineage
Q35199181	c-Met gene amplification is associated with advanced stage colorectal cancer and liver metastases
Q41644238	c-Met identifies a population of matrix metalloproteinase 9-producing monocytes in peritumoural stroma of hepatocellular carcinoma.
Q36544653	c-Met inhibitors attenuate tumor growth of small cell hypercalcemic ovarian carcinoma (SCCOHT) populations
Q27649203	c-Met inhibitors with novel binding mode show activity against several hereditary papillary renal cell carcinoma-related mutations
Q36551653	c-Met is a prognostic marker and potential therapeutic target in clear cell renal cell carcinoma
Q39735911	c-Met is essential for wound healing in the skin
Q36609706	c-Met overexpression in inflammatory breast carcinomas: automated quantification on tissue microarrays
Q35133627	c-Met recruits ICAM-1 as a coreceptor to compensate for the loss of CD44 in Cd44 null mice
Q35049178	c-Met signaling induces a reprogramming network and supports the glioblastoma stem-like phenotype.
Q37169357	c-Met targeted therapy of cholangiocarcinoma
Q34883707	c-Met-induced epithelial carcinogenesis is initiated by the serine protease matriptase
Q37998853	c-Met: A potential therapeutic target for hepatocellular carcinoma
Q61818143	c-Src Recruitment is Involved in c-MET-Mediated Malignant Behaviour of NT2D1 Non-Seminoma Cells
Q37205044	c-met is overexpressed in type I ovarian cancer: Results of an investigative analysis in a cohort of consecutive ovarian cancer patients
Q34438708	cMET Activation and EGFR-Directed Therapy Resistance in Triple-Negative Breast Cancer
Q37290053	cMET and phospho-cMET protein levels in breast cancers and survival outcomes
Q24337462	hTID-1 defines a novel regulator of c-Met Receptor signaling in renal cell carcinomas
Q36075298	mRNA profiling of the cancer degradome in oesophago-gastric adenocarcinoma.
Q64271350	miR-338-3p regulates the proliferation, apoptosis and migration of SW480 cells by targeting MACC1
Q34194306	miR‐340 inhibition of breast cancer cell migration and invasion through targeting of oncoprotein c‐Met
Q64240809	mutation causes muscular dysplasia and arthrogryposis
Q39100654	α-Syntrophin is required for the hepatocyte growth factor-induced migration of cultured myoblasts
Q84630708	β-catenin signaling involves HGF-enhanced HepG2 scattering through activating MMP-7 transcription

P6179	Dimensions Publication ID	1036162157
P356	DOI	10.1038/NRM1261
P3181	OpenCitations bibliographic resource ID	1261236
P698	PubMed publication ID	14685170

P50	author	Carmen Birchmeier-Kohler	Q128317532
P2093	author name string	Walter Birchmeier
		Ermanno Gherardi
		George F Vande Woude
P2860	cites work	Crystal structure of the extracellular segment of integrin alpha Vbeta3 in complex with an Arg-Gly-Asp ligand	Q24292425
		Molecular cloning and expression of human hepatocyte growth factor	Q24305558
		Identification of the Hepatocyte Growth Factor Receptor As the c- met Proto-Oncogene Product	Q24310794
		The Gab1 PH domain is required for localization of Gab1 at sites of cell-cell contact and epithelial morphogenesis downstream from the met receptor tyrosine kinase	Q24554529
		Neutralizing monoclonal antibodies to hepatocyte growth factor/scatter factor (HGF/SF) display antitumor activity in animal models	Q24629814
		Essential role of Gab1 for signaling by the c-Met receptor in vivo	Q24685688
		Crystal structures of NK1-heparin complexes reveal the basis for NK1 activity and enable engineering of potent agonists of the MET receptor.	Q27635335
		Crystal structure of the tyrosine kinase domain of the human insulin receptor	Q27730800
		Structure of a heparin-linked biologically active dimer of fibroblast growth factor	Q27760195
		Crystal structure of the NK1 fragment of human hepatocyte growth factor at 2.0 A resolution	Q27766028
		Crystal structure of the NK1 fragment of HGF/SF suggests a novel mode for growth factor dimerization and receptor binding	Q27766474
		Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.	Q27824766
		Epithelial-mesenchymal transitions in tumour progression	Q27860487
		A gene-expression signature as a predictor of survival in breast cancer	Q27860945
		Signaling of hepatocyte growth factor/scatter factor (HGF) to the small GTPase Rap1 via the large docking protein Gab1 and the adapter protein CRKL	Q28141139
		Mutation of the c-Cbl TKB domain binding site on the Met receptor tyrosine kinase converts it into a transforming protein	Q28210330
		Hepatocyte growth factor/scatter factor activates the ETS1 transcription factor by a RAS-RAF-MEK-ERK signaling pathway	Q28214429
		K252a inhibits the oncogenic properties of Met, the HGF receptor	Q28214703
		The semaphorin 4D receptor controls invasive growth by coupling with Met	Q28219215
		Induction of epithelial tubules by growth factor HGF depends on the STAT pathway	Q28259695
		A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family	Q28285975
		Interaction between Gab1 and the c-Met receptor tyrosine kinase is responsible for epithelial morphogenesis	Q28295920
		Placental defect and embryonic lethality in mice lacking hepatocyte growth factor/scatter factor	Q28307227
		Scatter factor/hepatocyte growth factor is essential for liver development	Q28504542
		Essential role for the c-met receptor in the migration of myogenic precursor cells into the limb bud	Q28506228
		Viable hypomorphic signaling mutant of the Met receptor reveals a role for hepatocyte growth factor in postnatal cerebellar development	Q28507121
		Coupling of Gab1 to c-Met, Grb2, and Shp2 mediates biological responses	Q28513246
		Activation of both MAP kinase and phosphatidylinositide 3-kinase by Ras is required for hepatocyte growth factor/scatter factor-induced adherens junction disassembly	Q36899460
		Evidence for the identity of human scatter factor and human hepatocyte growth factor	Q37574028
		Activation of NF-kappaB is essential for hepatocyte growth factor-mediated proliferation and tubulogenesis	Q39677451
		Regulation of scatter factor/hepatocyte growth factor responses by Ras, Rac, and Rho in MDCK cells	Q40021756
		Regulation of epithelial cell migration and tumor formation by beta-catenin signaling	Q40698690
		Requirement of Stat3 signaling for HGF/SF-Met mediated tumorigenesis	Q40755904
		Myocardial protection from ischemia/reperfusion injury by endogenous and exogenous HGF.	Q40761395
		A signaling adapter function for alpha6beta4 integrin in the control of HGF-dependent invasive growth	Q40765252
		Potent blockade of hepatocyte growth factor-stimulated cell motility, matrix invasion and branching morphogenesis by antagonists of Grb2 Src homology 2 domain interactions	Q40816900
		Phosphoinositide 3-kinase induces scattering and tubulogenesis in epithelial cells through a novel pathway	Q41024604
		Engineered mutants of HGF/SF with reduced binding to heparan sulphate proteoglycans, decreased clearance and enhanced activity in vivo	Q41052630
		Activated ras and ret oncogenes induce over-expression of c-met (hepatocyte growth factor receptor) in human thyroid epithelial cells	Q41109580
		Mutational analysis and molecular modeling of the N-terminal kringle-containing domain of hepatocyte growth factor identifies amino acid side chains important for interaction with the c-Met receptor	Q41458446
		Identification of a fibroblast-derived epithelial morphogen as hepatocyte growth factor	Q41656206
		Met-induced JNK activation is mediated by the adapter protein Crk and correlates with the Gab1 - Crk signaling complex formation	Q41711750
		Scatter factor is a fibroblast-derived modulator of epithelial cell mobility	Q42807925
		Mechanism of met oncogene activation	Q42811433
		Structural basis of oncogenic activation caused by point mutations in the kinase domain of the MET proto-oncogene: modeling studies	Q42828980
		A switch from p130Cas/Crk to Gab1/Crk signaling correlates with anchorage independent growth and JNK activation in cells transformed by the Met receptor oncoprotein	Q42832806
		Down-regulation of MET, the receptor for hepatocyte growth factor.	Q43649368
		Regulation of the mitogen-activated protein kinase signaling pathway by SHP2.	Q43847045
		A mechanism of cell survival: sequestration of Fas by the HGF receptor Met.	Q43894879
		Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas	Q45345804
		Molecular cloning of a new transforming gene from a chemically transformed human cell line.	Q45345810
		Hepatocyte growth factor/scatter factor (HGF/SF) signals via the STAT3/APRF transcription factor in human hepatoma cells and hepatocytes	Q45345818
		Morphogenetic mechanisms of epithelial tubulogenesis: MDCK cell polarity is transiently rearranged without loss of cell-cell contact during scatter factor/hepatocyte growth factor-induced tubulogenesis.	Q46366404
		Early treatment with hepatocyte growth factor improves cardiac function in experimental heart failure induced by myocardial infarction	Q46570566
		Evolutionary origins of vertebrate appendicular muscle	Q47653646
		The hepatocyte growth factor/Met pathway controls proliferation and apoptosis in multiple myeloma.	Q47982958
		In vivo targeting of SF/HGF and c‐met expression via U1snRNA/ribozymes inhibits glioma growth and angiogenesis and promotes apoptosis	Q48700301
		Genes that control the development of migrating muscle precursor cells	Q52163319
		Hepatocytes and scatter factor	Q68423197
		Radioimmunoscintigraphy of tumors autocrine for human met and hepatocyte growth factor/scatter factor	Q73814020
		Role of Gab1 in heart, placenta, and skin development and growth factor- and cytokine-induced extracellular signal-regulated kinase mitogen-activated protein kinase activation	Q28589835
		Beta4 integrin is required for hemidesmosome formation, cell adhesion and cell survival	Q28592841
		Liver regeneration	Q29614743
		The Caenorhabditis elegans EGL-15 Signaling Pathway Implicates a DOS-Like Multisubstrate Adaptor Protein in Fibroblast Growth Factor Signal Transduction	Q30167815
		Identification of an atypical Grb2 carboxyl-terminal SH3 domain binding site in Gab docking proteins reveals Grb2-dependent and -independent recruitment of Gab1 to receptor tyrosine kinases	Q30168876
		DOS, a novel pleckstrin homology domain-containing protein required for signal transduction between sevenless and Ras1 in Drosophila.	Q30176932
		Src homology 2-containing inositol 5-phosphatase 1 binds to the multifunctional docking site of c-Met and potentiates hepatocyte growth factor-induced branching tubulogenesis.	Q31538849
		Hepatocyte growth factor, a versatile signal for developing neurons	Q33589398
		Suppression of Ras-mediated tumorigenicity and metastasis through inhibition of the Met receptor tyrosine kinase	Q33943764
		The multisubstrate adapter Gab1 regulates hepatocyte growth factor (scatter factor)-c-Met signaling for cell survival and DNA repair	Q33969029
		Functional map and domain structure of MET, the product of the c- met protooncogene and receptor for hepatocyte growth factor/scatter factor	Q34267718
		Receptor tyrosine kinases as therapeutic targets: the model of the MET oncogene.	Q34314967
		Dysregulation of Met receptor tyrosine kinase activity in invasive tumors	Q34584046
		Smart drugs: tyrosine kinase inhibitors in cancer therapy	Q34710595
		Perspectives on the development of a molecularly targeted agent	Q34710684
		Activation of cdc42, rac, PAK, and rho-kinase in response to hepatocyte growth factor differentially regulates epithelial cell colony spreading and dissociation	Q34712138
		Small molecule tyrosine kinase inhibitors: clinical development of anticancer agents	Q35040797
		The "Gab" in signal transduction.	Q35082143
		How to make tubes: signaling by the Met receptor tyrosine kinase	Q35147372
		Invasiveness and metastasis of NIH 3T3 cells induced by Met-hepatocyte growth factor/scatter factor autocrine stimulation	Q35277738
		Molecular cloning and sequence analysis of cDNA for human hepatocyte growth factor	Q35307866
		Hepatocyte growth factor enhances vascular endothelial growth factor-induced angiogenesis in vitro and in vivo	Q35746501
		CD44 is required for two consecutive steps in HGF/c-Met signaling.	Q35805198
		Diverse tumorigenesis associated with aberrant development in mice overexpressing hepatocyte growth factor/scatter factor	Q35961109
		Scatter factor: molecular characteristics and effect on the invasiveness of epithelial cells	Q36223889
		Heparin induces dimerization and confers proliferative activity onto the hepatocyte growth factor antagonists NK1 and NK2.	Q36236835
		Motogenic and morphogenic activity of epithelial receptor tyrosine kinases	Q36236949
		Ezrin is an effector of hepatocyte growth factor-mediated migration and morphogenesis in epithelial cells	Q36268138
		Activation of the Met receptor by cell attachment induces and sustains hepatocellular carcinomas in transgenic mice	Q36326357
		Degradation of the Met tyrosine kinase receptor by the ubiquitin-proteasome pathway	Q36565319
		Activating mutations for the Met tyrosine kinase receptor in human cancer	Q36595980
		Met/HGF receptor modulates bcl-w expression and inhibits apoptosis in human colorectal cancers	Q36621835
		NK4, a four-kringle antagonist of HGF, inhibits spreading and invasion of human pancreatic cancer cells	Q36622822
		Molecular evolution and domain structure of plasminogen-related growth factors (HGF/SF and HGF1/MSP)	Q36704207
P433	issue	12
P407	language of work or name	English	Q1860
P304	page(s)	915-25
P577	publication date	2003-12-01
P13046	publication type of scholarly work	review article	Q7318358
P1433	published in	Nature Reviews Molecular Cell Biology	Q1573120
P1476	title	Met, metastasis, motility and more
P478	volume	4

Met, metastasis, motility and more

scientific article (publication date: December 2003)

Reverse relations